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Abstract 
 
Figueiredo P., 2020. Development of Lignin-based Nanoparticles for Cancer 
Therapy 
 
 
 
Lignin is part of the lignocellulosic biomass and represents the second most abundant 
biopolymer after cellulose. However, only about 2% of the annually isolated lignin is used for 
low-value applications, mainly due to its complex structure. The fabrication of lignin 
nanoparticles offers a structural and morphological control of the lignin polymer, which enables 
lignin to be used for high-value products in biomedical applications like drug delivery and tissue 
engineering. Therefore, the main aim of this thesis was to exploit the potential of the under-
investigated lignin-based nanoparticles as vehicles to deliver different therapeutic compounds 
for improved cancer therapy. Although multiple treatment options are available to treat cancer 
diseases, they still represent illnesses with very high incidence and mortality worldwide. 
Nanotechnology has opened doors to improve the limitations of current therapeutic modalities, 
such as chemotherapy or administration of immunomodulatory agents, by improving the 
solubility, stability and circulating half-life of the therapeutics, and by minimizing the systemic 
side effects. Firstly, different lignin-based nanoparticles were prepared and characterized, and 
their cytocompatibility investigated towards several cell lines. The ability of lignin nanoparticles 
to load different chemotherapeutic compounds was assessed, and drug release profiles were 
evaluated in two different buffers (pH 5.5 and 7.4). Secondly, after a carboxylation reaction of 
the original lignin polymer, the carboxylated lignin nanoparticles were surface modified with a 
polymer/peptide, as a proof-of-concept of the nanoparticles’ functionalization. The release 
profile of a poorly-water soluble cytotoxic compound (benzazulene) from the lignin 
nanoparticles was evaluated, and the in vitro antiproliferative effect investigated against 
several cell lines. Next, lignin polymers with different degrees of carboxylation were prepared 
in order to investigate the long-term stability of the resulting lignin nanoparticles at physiological 
conditions. After finding the optimal conditions in terms of stability, the lignin nanoparticles 
were further functionalized with a cell-penetrating peptide, and the cellular interactions of the 
resulting nanosystem were evaluated and compared with internalizing arginine-glycine-
aspartic acid peptide-functionalized lignin nanoparticles, using two- and three-dimensional cell 
culture models. Finally, the lignin nanoparticles were loaded with resiquimod, an agonist of the 
toll-like receptors 7 and 8 that can induce the re-education of M2 to M1-like macrophages, and 
further functionalized with a peptide that targets the mannose receptor expressed by the M2 
macrophages. Afterwards, the homing ability of these nanoparticles was investigated in vivo, 
using an orthotopic 4T1 triple-negative breast cancer model. The therapeutic effect of these 
nanosystems was studied in combination with a chemotherapeutic compound (vinblastine), 
and the immunological profile of the cells isolated from the tumors was compared. Overall, this 
thesis provides new insights on the use of lignin polymer as a novel starting material to develop 
lignin-based nanocarriers, in particular for cancer therapeutics.  
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1 Introduction 
 
Lignin is the second most abundant polymer, after cellulose, that can be obtained from 
renewable sources, and it comprises about 30% of the lignocellulosic biomass.1 Despite of its 
abundance, only 2% of the annually extracted lignin is used in low-value applications, such as 
polymer synthesis, and are used as dispersants, adhesives and fillers, and the remaining 98% 
is used for energy production and recovery of pulping chemicals.2–4 This is mainly due to the 
high polydispersity and complex structure of lignin that limits its use for other high-value 
applications. However, some chemical modifications in the lignin can be done to improve its 
properties. In addition, transforming raw lignin into lignin nanoparticles (LNPs) also allows the 
control of the morphology and structure of lignin.4–6 The preparation of LNPs may open an 
avenue for the development of different lignin-based materials even for high-value applications, 
such as drug delivery and tissue engineering.7   
Cancer is still one of the diseases with the highest incidence and mortality worldwide,8 
and despite all the improvements in the cancer treatment during the past years, the 
conventional chemotherapeutic drugs suffer from some limitations, including poor tumor-
specific drug delivery, low water solubility and adverse side effects upon repeated 
administration.9–11 To overcome these limitations, nanomedicines have emerged as a 
promising alternative to the conventional therapies, by improving the stability, solubility and 
circulation half-life of the therapeutic compounds, thus providing new tools for early detection, 
diagnosis, and superior treatment of cancer.9,12–15 The physicochemical properties of 
nanoparticles (NPs), such as size, shape, charge, and surface chemistry and functionalization, 
can be fine-tuned to alter the biodistribution and in vivo biological interactions of the NPs upon 
administration.16  
Besides the fact that NPs can benefit from the enhanced permeability and retention (EPR) 
effect, they can also be functionalized with several types of ligands that bind specifically to a 
certain target, enhancing their cellular internalization and delivery of their payloads, while 
minimizing their systemic side effects.9,17,18 Additionally, NPs can also be used for 
immunotherapy applications due to their ability to carry antigens and adjuvants, in order to 
increase their immunogenicity, and also enhance the NPs’ uptake by the antigen presenting 
cells (APCs), ultimately leading to an increased cross presentation of antigens to the cytotoxic 
T cells (CTLs).19 Moreover, tumor associated macrophages (TAMs) have also appeared as a 
promising target for cancer immunotherapy due to the dominant presence of 
immunosuppressive TAMs in the tumor microenvironment (TME) of certain tumors, and their 
phenotypic plasticity enables the re-education into an anti-tumor phenotype, also known as 
M1-like macrophages.20,21 
This thesis work started with the preparation and characterization of different lignin-
based NPs, and further evaluation of their cytocompatibility properties towards several cell 
lines. Then, the ability of LNPs to load different chemotherapeutic compounds was evaluated, 
and drug release profiles were investigated in two different buffers (pH 5.5 and 7.4). Next, a 
carboxylation reaction of the original lignin polymer was performed in order to increase the 
amount of functional groups for consequent surface modifications. As a proof-of-concept study, 
the carboxylated LNPs were functionalized with a polymer and/or peptide, and release profiles 
of a poorly-water soluble cytotoxic compound (benzazulene) loaded into the LNPs were 
evaluated. Also, the in vitro antiproliferative effect of benzazulene was measured towards 
several cancer cell lines. In order to investigate the long-term stability of the LNPs at 
physiological conditions, different lignin polymers with several degrees of carboxylation were 
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prepared. After finding the optimal conditions in terms of stability, the LNPs were further 
functionalized with a cell-penetrating peptide (DSS), and the cellular internalization of the 
resulting DSS-modified LNPs was evaluated and compared with internalizing arginine-glycine-
aspartic acid (iRGD)-functionalized LNPs, using two- and three-dimensional cell culture 
models. In the last study, the potential of the LNPs to load resiquimod was evaluated. 
Resiquimod is a compound that can induce the repolarization of M2- towards M1-like 
macrophages. The resiquimod-loaded LNPs were further functionalized with “mUNO”, a short 
peptide that targets the mannose receptor that is overexpressed in M2 macrophages. Homing 
ability of these LNPs to the macrophages in the TME was assessed, and the therapeutic effect 
of the resiquimod-loaded LNPs was studied in combination with a chemotherapeutic 
compound (vinblastine), by evaluating the immunological profile of the cells isolated from the 
tumors. 
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2 Literature overview  
 
2.1 Lignin-based materials 
 
Biorenewable polymers extracted from different sources have shown great potential as 
alternatives to commonly used metallic and organic materials for a variety of applications. They 
have attracted an increased attention from the research community due to their key 
advantages, which include biocompatibility, biodegradability, minimization of the 
environmental effects related with their usage, and low production cost.22–25 Lignocellulosic 
biomass is one example of biopolymers that is derived from plant and wood sources, and 
represents the most promising renewable carbon-containing resource on Earth.26,27 The 
composition of the lignocellulosic materials varies according to their origin and species (e.g., 
softwood, hardwood, and grass), and they are constituted by 30–50% of cellulose, a polymer 
composed by glucose units, 20–35% of hemicellulose, a heteropolymer containing different 
polysaccharides, and 15–30% of lignin.24,28  
Although lignin is a very abundant raw material, only about 2% of the annually extracted 
lignin from the woody biomass is used for low-value applications, including the synthesis of 
environmentally friendly polymers, typically used as dispersants, adhesives and fillers, while 
ca. 98% is burned in recovery incinerators for energy production and recovery of pulping 
chemicals.2–4 This low utilization might be ascribed to the complex and variable lignin structure, 
high polydispersity, and non-miscibility with host polymer matrix.3,27,29 To overcome these 
limitations, different procedures to chemically improve its properties and transform the original 
lignin into value-added fuels and chemicals can be done, as well as preparing LNPs that will 
improve the blending ability with host matrix and offer a morphological and structural control 
of the lignin.4–6 Furthermore, the fabrication of lignin nanostructures also open up doors for the 
development of lignin-based materials for other high-value applications, including tissue 
engineering materials and drug delivery systems.7 According to the statistics given by PubMed, 
studies related to the preparation of LNPs started to be published in 2006, and few reports 
have been published until now; while publications about the use of lignin polymer have been 
done since 1980 (Figure 1A). Moreover, among other kind of applications, only ca. 10% of the 
publications with LNPs are related to the nanotechnology and biomaterials field (data from 
Web of Science, Figure 1B). This means that the use of lignin as starting material for the 
production of NPs started recently, and there are many parameters that should be studied 
when considering LNPs for biomedical applications.  
 
 
Figure 1. A) Number of publications searching keywords ‘Lignin’ and ‘Lignin nanoparticles’, 
until October 2019 (Source: PubMed). B) Percentage of publications with LNPs, according to 
their field of application (Source: Web of Science). 
 Literature Overview  
 
 4  
 
2.1.1 Introduction to lignin 
 
Lignin comprises about 30% of the lignocellulosic biomass, and it is usually covalently bonded 
to the hemicellulose/cellulose structures, as represented in Figure 2A.1 The primary function 
of lignin is to give strength and rigidity to the primary and secondary cell walls, acting as a 
structural component. Additionally, it is also responsible for the transport of water/solutes in 
the vasculature system of the plants, and for protection against environmental stresses, such 
as invasions by phytopathogens.1,30,31   
Structurally, lignin is a highly branched biomacromolecule that comprises three units, so-
called p-hydroxyphenyl (H), guaiacyl (G) and syringyl (S) units, which are originated from their 
respective monomers (monolignols) p-coumaryl, coniferyl and sinapyl alcohols (Figure 
2B).32,33 The synthesis of the monomers initiates by the deamination of the aromatic 
phenylalanine and further polymerization by a cascade of peroxidases and oxidases. Then, 
the lignin biosynthesis continues with a sequence of hydroxylation, methylation and reduction 
reactions by certain enzymes, resulting in the formation of the abovementioned three basic 
units.27,34 Afterwards, the produced monolignols are transported to the apoplast through the 
plasma membrane, which are then activated to form the monolignol radicals that will 
polymerize to produce the lignin polymers, a process that is intermediated by enzymes like 
peroxidases, laccases and other polyphenol oxidases.34,35 Regarding the bonds between 
monomers in the lignin structure, more than 50% corresponds to β-O-4′ ether linkages, which 
are the main target for most of the degradation mechanisms. Additionally, a smaller proportion 
of other types of linkages can be found in the lignin structure, including β-5 phenylcoumaran, 
β-β′ resinol, α-O-4′ ether, 4-O-5′ diphenyl ether, 5-5 biphenyl and β-1′ diphenyl methane, but 
these are more difficult to degrade during the traditional processing methods due to the carbon-
carbon bond formation (Figure 2C).28,36,37 Both chemical linkages and proportion of the 
monolignols affects the rigidity of the lignin structure, and vary according to the source of the 
lignocellulosic biomass.24,27 For example, lignin obtained from softwoods is mainly composed 
by guaiacyl units connected by carbon-carbon and ether bonds, while lignin extracted from 
hardwoods presents equal amounts of syringyl and guaiacyl units, and grass lignin possesses 
the three monolignols in its structure.30,33  
After acid or alkali treatment, the colorless lignin in the native state becomes of brown or 
dark brown color.38 As a biorenewable polymer, the main advantages and properties of lignin 
polymers include their availability in large amounts at low prices, antifungal, antimicrobial and 
antioxidant properties, biodegradability, fire-retardant properties, and ability to absorb UV-
radiation.2,24,39–42 Other physicochemical properties make lignin an attractive polymer for the 
renewable energy industry and fabrication of other lignin-based products. Depending on the 
extraction process, the hydrophilic or hydrophobic nature of lignin can offer good rheological 
and viscoelastic properties, film-forming ability, and also compatibility with several industrial 
chemicals.27 Additionally, the presence of reactive functional groups on its structure allows the 
conjugation with targeting moieties, such as peptides or antibodies, or the production of graft 
copolymers.7,27 Moreover, due to its content in phenolic, hydroxyl, carboxyl and sulfonate 
functional groups, which vary according to the extraction process, the lignin polymer can be 
chemically modified using different approaches, allowing the lignin valorization and its use in 
the preparation of value-added products for a variety of applications (Figure 2D).26,43 
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Figure 2. Schematic representation of A) lignin distribution in lignocellulosic biomass; B) 
monolignol monomers species present in lignin, and C) main linkages present in the lignin 
structure. D) Summary of the main industrial processes for lignin extraction, possible chemical 
modifications on the lignin structures and main applications. Copyright © 2018 Elsevier B.V. 
Adapted and reprinted with permission from ref.7  
 
 
Processing methods for lignin extraction and chemical modifications 
 
Generally, the extraction of lignin from lignocellulosic biomass is a process where the lignin is 
broken down into lower molecular weight compounds, whose physicochemical properties are 
influenced by the source and extraction method of lignin.26–28 The most commonly used 
processes to extract lignin are kraft, sulfite, and organosolv processes.44,45 These methods are 
different in several key parameters that influence the extraction process, including the ability 
of the chosen solvent/solute to participate in the lignin fragmentation process, to dissolve lignin 
molecules and to prevent the lignin recondensation, as well as the effects of temperature, pH 
and pressure on the system.28,44 Consequently, the extracted lignin presents distinctive 
features and properties that vary according to the applied extraction method, affecting mainly 
the lignin solubility and molecular weight, and also the amount of functional groups on the lignin 
structure.2,7,27 
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Kraft process is the most commonly used method to process lignocellulosic materials, 
being responsible for ca. 85% of the extracted lignin.46 Conventionally, the delignification 
process using the Kraft methodology initiates with the lignin dissolution after cleaving the ether 
linkages, in sodium hydroxide and sodium sulfide (white liquor) at high temperature (ca. 170 °C) 
and pH values ranging from 13 to 14.44,45,47,48 Under these high pH values the phenolic hydroxyl 
groups will ionize, allowing the solubilization of the lignin that is consequently isolated from the 
remaining alkaline solution (black liquor) after lowering the pH to 5–7.5, by acid-mediated 
precipitation (e.g., sulfuric acid).27,49,50 The isolated kraft (also called alkali) lignin is 
hydrophobic, usually soluble in alkali or organic solvents, and it possesses an average 
molecular weight of 1000–3000 Da, but it can go up to 15000 Da.2,45,51 In terms of functional 
groups, kraft lignin exhibits some amount of sulfur groups (1–2 wt-%) on its structure, in 
addition to the typical carboxyl, phenolic hydroxyl and methoxy groups.27 The LignoBoost 
Technology has been used to commercially produce high quality softwood kraft lignin.52 In 
2013, Domtar’s Plymouth (North Carolina Mill, USA) was the first industry to commercialize 
high-quality lignin as a by-product of their pulping process, which is now market as BioChoice® 
Lignin.53 In 2015, the second commercially available softwood kraft lignin using the LignoBoost 
technology was started at the Stora Enso (Sunila Mill, Kotka, Finland), which is now called 
Lineo™.54 More recently, UPM Biochemicals (Finland) have also started to produce UPM 
BioPiva™ softwood kraft lignin.55 
The sulfite process is another extraction method that is commonly used in the pulp and 
paper industry, allowing to obtain lignosulfonates.44 In this method, the pH of the system can 
vary from 2 to 12, according to the pulping chemicals mix and its dosage, and the reaction 
occurs at temperatures that can range between 120 and 180 °C.7,44 This pulping process starts 
with the reaction between lignin and a sulfite, where the lignin and free sulfurous acid react to 
form lignosulfonic acid. Then, the presence of calcium, sodium, ammonium or magnesium as 
counter ions leads to the formation of water-soluble lignosulfonates, which are further 
fragmentated.27,44 The hydrolysis and dissolution of the lignin is due to the incorporation of 
polar sulfonic groups in its backbone, whereas the cellulose remains as solid.45,47 
Consequently, the sulfur content of the lignosulfonates can vary between 4 and 8 wt-%, and 
they also exhibit higher average molecular weights (1000–50000 Da) than kraft lignin, as a 
result from the incorporation of sulfonate groups into the lignin structure.44,45,47 Nevertheless, 
the sulfite method has some disadvantages, including the modification of the lignin structure 
due to the formation of new CC bonds, and also the presence of high content of ash and other 
impurities after the extraction process.45 
Other extraction processes have emerged as promising alternatives to the conventional 
kraft and sulfite pulping methodologies. For example, the organosolv process involves the use 
of organic solvents (e.g., ethanol, methanol, acetic and formic acid), usually mixed with water, 
as the delignifying agents on the treatment of lignocellulosic biomass, and at temperatures 
ranging from 170 to 190 °C.45,56–58 Under this treatment, the lignin and hemicellulose are 
partially dissolved, and the recovery and separation of these two components are further 
carried out by adjusting the temperature, pH and concentration of the organic solvent, leading 
to the precipitation of lignin or the evaporation of the organic solvent.58,59 With this process, the 
obtained lignin is sulfur-free, preserves its native structure and presents lower molecular 
weights (500–5000 Da) and ash-content.45,47,56,60 Moreover, the organosolv pulping is a more 
environmentally friendly method and less aggressive compared to abovementioned processes, 
and the organosolv lignin is more suitable for further conversion and valorization.7,45 
Although lignin can be used without any chemical modification, by incorporating the 
original lignin into a polymeric matrix to reduce production costs and improve the properties of 
 Literature Overview  
 
 7  
 
the end product (e.g., as UV-light stabilizer, additive, filler, or antioxidant), the phenolic and 
aliphatic hydroxyl groups in the chemical structure can be modified in order to develop new 
lignin-based materials.2,61–64 For that, different strategies can be done, such as: (i) lignin 
depolymerization or fragmentation, using processes like pyrolysis, hydrogenolysis, oxidation, 
hydrolysis and gasification, in which the lignin is cleaved and converted into valorized small 
fragments containing aromatic rings that are further used as fuels and basic chemicals or 
oligomers;65,66 (ii) creating new chemically active sites on the original lignin polymer (e.g., using 
hydroxyalkylation, amination, nitration, sulfomethylation and sulfonation reactions);2 (iii) 
chemically modifying the hydroxyl groups on the original lignin structure (such as, alkylation, 
esterification, etherification, phenolation and urethanization);2 and (iv) production of graft 
copolymers, in which the polymer chains are connected to the hydroxyl groups on the lignin 
backbone.29 Both the reactivity of the functional groups and the structural characteristics of the 
lignin to be used will influence the efficacy of these chemical modifications and, consequently, 
the end-use application(s) of the produced lignin-based materials.7  
 
 
2.1.2 Preparation of lignin-based materials 
 
Although lignin is still an underexploited natural biomaterial, its potential as a starting material 
to develop more sophisticated nanomaterials has been recently emerging. Despite the high 
availability of lignin, its applications are restricted by the complex macromolecular structure 
that depends on the source and extraction method applied to isolate the lignin. However, this 
issue can be circumvented when the raw lignin is transformed into NPs with uniform size and 
shape.67 In this way, different lignin-based nanomaterials have been prepared, including NPs, 
nanotubes, nanofibers, and hydrogels.3,24,68 The presence of several functional groups on the 
lignin structure has been exploited to chemically modify the lignin and, therefore, increase the 
potential for a variety of applications, such as the preparation of nanocomposites, and also for 
biomedical applications (e.g., drug delivery and tissue engineering).7 For these purposes, 
different methods have been used to prepare a variety of lignin-based nanostructures, with 
different shapes and properties, such as anti-solvent precipitation, solvent exchange, 
interfacial crosslinking, sonication, and polymerization (Figure 3).3,7  
 
 
Figure 3. Representation of the different methodologies to produce LNPs. Copyright © 2018 
Elsevier B.V. Reprinted with permission from ref.7 
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In addition to NPs, lignin has also been used in the preparation of hydrogels, mainly due 
to its intrinsic properties, such as biodegradability, biocompatibility, low toxicity, predisposition 
to undergo enzymatic degradation, and environmentally friendly properties as a natural 
polymers.24 For this, lignin has been incorporated into different types of hydrogels in order to 
facilitate their formation and also to enhance their properties, which can also be used for drug 
delivery and tissue engineering applications.24  
 
 
Anti-solvent precipitation 
 
Generally, the anti-solvent precipitation approach to prepare LNPs relies on the self-assembly 
of the lignin, in which water or compressed liquid carbon dioxide (CO2) can be used as anti-
solvent, and a variety of different solvents are used to dissolve lignin, including tetrahydrofuran 
(THF), N,N-dimethylformamide (DMF), ethanol (EtOH), water/acetone, or water/THF/EtOH.69–
74 Besides the composition of the anti-solvent/solvents used in this method, other parameters 
can be changed in order to fine-tune the size and shape of the resulting NPs, including 
temperature, injection rate of the solution, pressure, initial concentration of the lignin solution, 
among others.70 For example, Li et al. (2016) studied the effect of the dropping speed of water 
on the size of the lignin nanocapsules, after adding the water into a solution containing kraft 
lignin in EtOH at the initial concentration of 2.285 mg/mL, until the water content of the resulting 
solution reached 90%.73 They found out that the average size of the nanocapsules was 
decreased when the dropping speed of water was increased from 0.0076 to 0.2 mL/s, reaching 
a plateau where the size no longer decreased even when the dropping speed was increased 
(0.4 mL/s). This trend was probably due to the fact that the self-assembly process of the lignin 
micellization and its aggregation morphology were driven by kinetics and thermodynamics. 
Therefore, when the dropping speed of the water was too fast, the nanocapsules could not 
reach a thermodynamically stable structure, because there was not enough time to grow.73 
Additionally, Xiong et al. (2017) also observed the same tendency for the effect of the dropping 
speed of water in the size of lignin nanospheres.75 After adding the water at dropping speeds 
ranging from 2 to 8 mL/min into an enzymatic hydrolysis lignin solution in THF at initial 
concentration of 0.5 mg/ml, the size of the nanospheres decreased from ca. 315 nm to 190 
nm, respectively.  
In another study, Myint et al. (2016) studied the influence of temperature and pressure 
on the size and morphology of the NPs, using compressed liquid CO2 as the anti-solvent, and 
DMF to dissolve the kraft (alkali) lignin.70 When the pressure was constant, they noticed that 
the particle size and polydispersity index (PDI) were increased as the temperature applied in 
the system was increased, because aggregation/coalescence phenomena were observed to 
a higher extent. Also, the NP morphology was affected by the operating pressure. While 
keeping the temperature constant, the NPs were more aggregated and fused at low pressure 
(7.5 MPa) than the NPs fabricated at high pressures (15.0 MPa).  
Using an industrially scalable method, Lintinen et al. (2018) assembled a closed cycle 
process for the production of colloidal lignin particles (CLPs), where a concentrated solution of 
softwood kraft lignin was dissolved in a mixture of THF/EtOH/water and added into the anti-
solvent water, leading to the instantaneous self-assembling of lignin to form spherical CLPs 
with an average size of 200 nm and surface charge of −40 mV.74 Additionally, this closed cycle 
system allowed full recovery of the solvents, with a low energy consumption.  
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Solvent exchange  
 
In the solvent exchange method, or dialysis process, the lignin dissolved in an organic solvent 
(e.g., THF or THF/methanol) is introduced into a dialysis membrane, which is further immersed 
in deionized water during 24 h, to allow the precipitation of the lignin upon the replacement of 
the organic solvent with water, possibly through a nucleation-growth mechanism.76,77 In this 
method, the pre-dialysis concentration of the lignin solution seems to play an important role on 
the size of the LNPs. Lievonen et al. (2016) studied the effect of lignin concentrations ranging 
from 1 to 20 mg/mL on the particle size and PDI.76 A minimum particle size (ca. 200 nm) and 
PDI (0.15) was obtained when the pre-dialysis lignin concentration was 1 mg/mL, while the 
particle size and PDI increased to 2000 nm and 0.56, respectively, when the initial 
concentration was 20 mg/mL. This effect might be ascribed by the fact that when higher 
concentrations of lignin are used, there is more lignin available for the growth of the NPs, and 
the nucleation-growth phenomenon is so fast that NPs with different sizes are formed, 
explaining the higher size- and PDI-values obtained. When lower concentrations of lignin are 
introduced into the dialysis membrane, there is a lower probability of nucleus formation, 
decreasing the chance to form larger particles and, therefore, the average size of the NPs and 
the PDI-values were decreased.  
Lintinen et al. (2016) also prepared LNPs with different morphologies via solvent 
exchange, after pre-modification of the pre-dialysis lignin.78 For that, the lignin was mixed with 
different ratios of iron(III) isopropoxide [Fe(OiPr)3] in THF, and further submitted to a 
condensation reaction, where the condensation of the OH groups occurred to form Fe–O–C 
lignin bonds. This was followed by a hydrolysis step, in which water was added to allow the 
hydrolysis of the isopropoxy-groups and the condensation of adjacent Fe(OiPr)-moieties. For 
example, fishnet-type open network structures were obtained upon fast hydrolysis of equimolar 
ratios of –OH groups on the lignin and Fe(OiPr)3. However, a controlled hydrolysis prevents 
the Fe:LNPs from fusing together, leading to the formation of small solid particles. When the 
ratio of OHlignin:Fe(OiPr)3 was increased to 3:1, lignin clusters were partially covered with the 
Fe(OiPr) moieties, and upon a rapid or controlled condensation, they can fuse together to form 
larger solid particles or hollow spheres, respectively. 
 
 
Interfacial crosslinking and ultrasonication 
 
The interfacial crosslinking technique requires the mixture of an aqueous and oil phases, with 
or without the use of surfactants and crosslinking agents, leading to the formation of precursor 
microemulsions to generate particles after crosslinking of the dispersed materials.79,80 
Ultrasonication can also be used to assist and generate the microemulsions.80,81 Using this 
approach, Yiamsawas et al. (2014) synthesized lignin hollow nanocapsules with an average 
diameter of 150–200 nm and an aqueous core that allowed the encapsulation of different 
hydrophilic compounds,81 overcoming the limitation of the abovementioned anti-solvent 
precipitation and solvent exchange methods that generally allow the encapsulation of 
hydrophobic molecules. For that, lignosulfonic acid sodium salt or kraft lignin was dissolved 
with MilliQ-water, mixed with cyclohexane containing polyglycerol polyricinoleate as surfactant, 
and then ultrasonicated to create a stable microemulsion. Posteriorly, an overnight 
polyaddition reaction was conducted at the interface of the microemulsion droplets after adding 
toluene diisocyanate in cyclodextran to the previously prepared emulsion. A water-soluble 
lignin (lignosulfonate) was also used by Chen et al. (2016) to generate oil-in-water 
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microemulsions and preparing pH-sensitive nanocapsules for encapsulation of hydrophobic 
molecules.82 In this case, the lignosulfonate was previously grafted with allyl groups via 
etherification, and the microemulsion was then conducted by ultrasonication, in which the 
modified lignosulfonate and the surfactant (sodium dodecyl sulfate) were dissolved in the water 
phase, while the oil phase contained butyl acetate, co-stabilizer (hexadecane), an initiator and 
the cross-linker. Both lignosulfonate and cross-linker contacted at the water and oil interface, 
and reacted by free radical induced thiol–ene crosslinking reaction. 
Ultrasonication is a process based on a phenomenon called cavitation, in which occurs 
the formation of cavities and further creation of radicals. Different parameters can affect the 
formation of radicals, including the type of solution, temperature and pressure of the system, 
and ultrasound settings (e.g., duration and power).83–85 When using lignin solutions, the nature 
of the lignin polymer can also affect the composition and structural changes of the obtained 
LNPs.85 For example, Kim et al. (2013) prepared ionically crosslinked chitosan–lignosulfonate 
NPs with antibacterial properties via ultrasonication.86 After selecting the best conditions for 
the several parameters tested, including the pH-value (4.5, 5 and 6), sonication time (2, 5, 8 
and 10 min), non-ionic surfactants (poloxamer 407 or Tween 80) and concentration of both 
chitosan and lignosulfonate, the preparation of the NPs was successful. The lignosulfonate in 
water exhibited sulfonate groups (SO3−), which are anionic polyelectrolytes acting as counter 
ions to prepare chitosan NPs with increased stability. The best conditions to prepare the 
smallest NPs with low PDI were found after adjusting the pH of the chitosan to 5, the sonication 
time was set to 8 min, using 1% (v/v) of poloxamer as surfactant, and a chitosan/lignosulfonate 
mass ratio set as 2:1. Besides the abovementioned parameters, the effect of the ultrasonic 
intensity on the preparation of LNPs was evaluated by Wang et al. (2019) using the antisolvent 
precipitation method assisted by ultrasonic sonication, with ultrasonic intensities of 0, 100, and 
200 W, after dropping of water into the acetylated alkali lignin/THF solution at the final 
concentration of 2.0 mg/mL.87 Different sizes and shapes of the LNPs were observed when 
using different ultrasonic intensities: (i) without ultrasonic treatment (0 W), the prepared LNPs 
presented large average size, irregular shape, and broad size distribution; (ii) a mild ultrasonic 
treatment (100 W) allowed the preparation of more regular and well-separated LNPs, but still 
with a broad diameter distribution (ca. 200−800 nm); and (iii) with a high ultrasonic intensity 
(200 W), the LNPs exhibited good sphericity and proper size distribution.  
 
 
Polymerization and electrospinning 
 
Polymerization technique can be employed to produce advanced lignin-based materials, in 
which lignin is previously grafted with other polymers, for example, either via atom transfer 
radical polymerization (ATRP), or ring-opening polymerization.88,89  
Using an ATRP approach, Liu et al. (2015) grafted 2-(dimethylamino)ethyl methacrylate 
(DMAEMA) onto the lignin-based macroinitiators, resulting in a hyperbranched structure 
composed of a hydrophobic lignin backbone and multiple cationic hydrophilic arms of the 
DMAEMA polymer that efficiently compacted DNA into this structure, for potential gene 
delivery applications.88 In another study, Kai et al. (2015) fabricated a series of poly(methyl 
methacrylate) (PMMA) grafted lignin copolymers through ATRP, using different lignin:PMMA 
mass ratios (5.6% to 46.1%), rendering copolymers with different PMMA chain lengths and 
properties.89 Posteriorly, these copolymers were blended with poly(ε-caprolactone) (PCL) to 
form nanofibrous composites via electrospinning, improving the tensile strength and Young's 
modulus of the as-prepared nanofibrous composites, with good biocompatibility and improved 
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attachment, interactions and proliferation of human dermal fibroblasts for biomedical 
applications. 
A ring-opening polymerization methodology can also be used to prepare lignin-based 
composites. For example, Kai et al. (2017) fabricated lignin–poly(ε-caprolactone-co-lactide) 
(lignin–PCLLA) copolymers, with different mass ratios of the lignin, PCL and ɩ-lactide polymers, 
via solvent-free ring-opening polymerization.90 Posteriorly, these copolymers were blended 
with PCL or poly(ɩ-lactic acid) (PLLA) by electrospinning, resulting in the formation of 
nanofibers with sizes ranging from 300 to 500 nm. The incorporation of the lignin polymer in 
both PCL/lignin−PCLLA and PLLA/lignin−PCLLA nanofibers resulted in the improvement of 
mechanical properties, as well as in vitro biocompatibility and antioxidant activity, suggesting 
that these copolymers and nanofibers could be used for biomedical or other healthcare 
applications. In another study conducted by the same research group, poly(lactic acid) (PLA)–
lignin composites were engineered using the same approach, in which the content of alkylated 
lignin in the composites varied from 10 and 50%, and the grafted PLA chain length ranged 
from 5 to 38.91 The resulting copolymers were blended with PLLA and engineered into 
PLLA/PLA-lignin nanofibrous composites through electrospinning. It was observed that the 
copolymers comprising a higher content of lignin resulted in the production of thinner 
nanofibers, which can be ascribed to the low molecular weight of this copolymer and, therefore, 
a decreased viscosity of the spinning solution. Furthermore, the higher lignin content 
copolymer also showed the highest antioxidant activity among all the PLLA/PLA-lignin 
nanofibers, due to the intrinsic antioxidant property of the lignin polymer. Additionally, the 
lowest content of lignin in the PLLA/PLA-lignin nanofibers exhibited good biocompatibility and 
induced higher cell proliferation on: (i) PC12, a common cell line used in neurotoxicological 
studies and nerve regeneration; (ii) human dermal fibroblasts (HDFs), a cell line that exists 
within the dermis layer of human skin and presents a critical role in the wound healing process; 
and (iii) human mesenchymal stem cell (MSCs), which are multipotent stromal cells capable 
to differentiate into several cell types, such as bone cells, myocytes, nerve cells and 
chondrocytes. Overall, these results suggested that such lignin-based materials present high 
potential in the fabrication of scaffolds for tissue engineering applications. 
 
 
Hydrogels 
 
Hydrogels comprise a 3D network of hydrophilic polymers that form bonds between polymer 
chains and allow a superior absorption of water compared to their own dry weigh, being 
generally classified according to the chemical or physical interactions in the 3D structure 
network: (i) chemical hydrogels, prepared by converting hydrophobic monomers and polymers 
into hydrophilic ones and cross-linking water-soluble monomers and polymers, connected 
through covalent bonds, and (ii) physical hydrogels, which present networks linked together by 
secondary forces, such as ionic forces, hydrogen bonds, van der Waals interactions, and 
hydrophobic forces.92–94 In the past years, it has been observed an increased demand on the 
fabrication of hydrogels based on natural polymers in preference to the synthetic polymers, 
mainly due to their low toxicity, biocompatibility and biodegradability, responsiveness to 
enzymatic degradation and their intrinsic eco-friendly properties.92,95 Among other biopolymers, 
lignin has been used to develop different types of hydrogels in order to facilitate the hydrogels’ 
formation and improve their properties for a wide range of applications, including wound 
dressings, drug delivery and tissue engineering.7,24 After mixing lignin and cellulose in an 
alkaline solution, and further chemical cross-linking with epicholohydrin, Ciolacu et al. (2012) 
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fabricated cellulose-lignin hydrogels for drug delivery aplications.96 By controlling the 
composition of the hydrogels and increasing the lignin content in the matrices, it was possible 
to change the swelling process and increase the release of polyphenols from the hydrogels. A 
radical polymerization assisted by ultrasonication was used by Wang et al. (2016) to prepare 
lignosulphonate-grafted poly(acrylic acid-co-poly(vinyl pyrrolidone)) hydrogels to incorporate 
amoxicillin, exhibiting a pH-responsive and controlled drug release, with improved release 
profiles in simulated intestinal fluids compared to the simulated gastric fluids.97  
In another study, Diao et al. (2014) synthesized temperature sensitive lignin 
thermogelling graft copolymers using ATRP, after grafting multiple polymer chains of a block 
of brush-like random copolymer of poly(ethylene glycol) (PEG) and poly(propylene glycol) 
(PPG) and a block of poly(N-isopropylacrylamide) (PNIPAAm) onto the lignin core.98 
PNIPAAm-block-PEG/PPG and PNIPAAm-random-PEG/PPG copolymers with different block 
architecture were obtained, and when grafted onto the lignin core, were found to play an 
important role in the hydrogel formation. The PNIPAAm-block-PEG/PPG copolymer exhibited 
thermogelling behavior going from a solution at low temperatures to a hydrogel at 32–34 °C, 
and then to a dehydrated gel at higher temperatures; however, when the PNIPAAm-random-
PEG/PPG copolymer was grafted onto lignin using the same monomer ratio, the formation of 
hydrogel did not take place at any temperature. In this formulation, the PNIPAAm was crucial 
for the gelling at the critical gelation temperature, and the PPG chains can contribute to the 
water retention by balancing the hydrophilicity/hydrophobicity of the hydrogel network at the 
temperatures up to 52 °C. The fabricated hydrogel can experience a thermogelling transition 
at a temperature lower than human body temperature and higher than room temperature, 
indicating that it can be used for drug delivery and tissue engineering (e.g., stem cells culture 
and differentiation).  
 
 
2.1.3 Biomedical applications of lignin-based nanomaterials 
 
The fabrication of lignin-based nanomaterials offers crucial advantages, including the 
improvement of the properties of polymer blends, and a higher antioxidant activity due to the 
higher surface area-to-volume ratios.4,69,71 Moreover, the presence of functional groups on the 
lignin structure that can be easily chemically modified increases the potential of the LNPs for 
a wide range of biomedical applications.7 As a result of their intrinsic properties, lignin-based 
nanomaterials present a great potential to be used in surface coatings in the preparation of 
nanocomposites and stabilization of Pickering emulsions, for example, in drug/gene delivery 
and tissue engineering.7 The main biomedical applications and preparation methods of lignin-
based nanomaterials, and respective outcomes are summarized in Table 1. 
 
Table 1. Overview of the main biomedical applications of lignin-based materials, with reference 
to the type of lignin, preparation method and main outcomes of these materials. 
Type of Lignin 
(Shape) 
Preparation 
Method 
Outcome Ref. 
Antioxidant Properties  
Enzymatic 
hydrolysis 
lignin 
(Spherical) 
Anti-solvent 
precipitation 
Besides the influence of the total phenolic content, the particle size 
was shown to have a proportional effect on the antioxidant activity of 
the LNPs, where smaller NPs exhibited the highest activity. 
99 
Organosolv 
lignin 
(Nanospheres) 
Supercritical 
anti-solvent 
process 
The nanosized lignin (ca. 144 nm) exhibited much higher antioxidant 
ability compared to the irregular non-nanoscale lignin (around 1–100 
μm). 
69 
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Alkali lignin 
(Nanofibers) 
Polymerization 
and 
electrospinning 
Different lignin−PCLLA copolymers were prepared, with molecular 
weights ranging from 10 to 16 kDa and glass transition temperatures 
from −40 to 40 °C. The incorporation of lignin copolymers greatly 
enhanced the antioxidant properties of the resulting copolymers, 
compared to the PCL or PLLA counterparts.  
90 
UV Absorbing Capability  
Alkali lignin 
(Spherical) 
Liquid 
precipitation 
method 
Pure PVA films, PVA films with raw lignin, and PVA films with LNPs 
were fabricated. The films with LNPs exhibited better performance for 
UV absorption then the ones containing raw lignin, due to the 
presence of more phenolic groups on the surface of the NPs. 
100 
Organic acid 
lignin 
(Spherical) 
Solvent 
exchange  
The lignin particles (dosage of 5%) presented a high ability to enhance 
the sun protection factor values of lotions (by 2.80–3.53), showing also 
UVA/UVB values in the range of 0.69–0.72. Additionally, the addition 
of lignin particles to the lotion improved the antioxidant and UV 
protection abilities, suggesting that lignin can have a broad-spectrum 
skin photo-protection effect.  
101 
Acetylated 
alkali lignin 
(Spherical) 
Ultrasonication 
The addition of LNPs with smaller size enhanced the sunscreen 
performance of a commercial pure cream compared to the LNPs with 
larger size. 
87 
Antimicrobial Properties  
Kraft lignin 
(Spherical) 
Anti-solvent 
precipitation 
method 
The as-prepared Ag+-infused EbNPs, coated with a cationic 
polyelectrolyte (PDAC), showed higher antimicrobial activity and 
inferior environmental impact than metallic AgNPs. 
102 
Kraft lignin 
(Spherical) 
Ion and solvent 
exchange 
The AgCLPs showed high antibacterial efficacy, with low silver 
loading, even without the cationic polyelectrolyte coating. 
77 
Chitosan-
lignosulfonate 
(Spherical) 
Ultrasonication  
The chitosan-lignosulfonate complexes were found to have and 
increased antibacterial effect on both gram-negative and gram-
positive bacteria, compared to the chitosan alone.  
86 
Pickering Emulsions  
Kraft lignin 
(Spherical) 
Anti-solvent 
precipitation 
method 
The adsorption of cationic lignin onto the CLPs originated positively 
charged particles that provided an improved stability in a wider range 
of Pickering emulsions at pH values ranging from 2 to 6, compared to 
the irregular lignin particles or the regular CLPs. This might be 
ascribed to their pH-dependent surface charge, amphiphilicity, and the 
intermolecular stabilization due to the electrostatic and cation-π 
interactions of the cationic CLPs. 
103 
Kraft lignin 
(Spherical) 
Interfacial 
crosslinking 
Larger lignin particle size led to better stability and increased emulsion 
drop size. 
79 
Alkali lignin Polymerization 
Water-insoluble lignin was grafted with 2-(diethylamino)ethyl 
methacrylate (DEAEMA), rendering a polymer that presented CO2/N2-
switchability of dispersion/precipitation, correlated to the graft density 
and chain length of DEAEMA units, which can be used as a surfactant 
for Pickering emulsions. 
104 
Drug and Gene Delivery  
Alkaline lignin 
(Spherical) 
Anti-solvent 
precipitation 
method 
Lignin was self-assembled with resveratrol and iron oxide magnetic 
NPs to form a stable nanodrug carrier that showed and improved drug 
accumulation and tumor reduction in vivo, along with lower adverse 
effects than the free resveratrol. 
105 
Enzymatic 
hydrolysis 
lignin 
(Spherical) 
Anti-solvent 
precipitation 
method 
Lignin hollow NPs were loaded with doxorubicin, and covered by 
magnetic NPs and folic acid through layer-by-layer self-assembling. 
As a result, the folic-magnetic-functionalized lignin hollow NPs 
answered to the magnetic field and targeted the folic acid receptors, 
increasing the cellular uptake of NPs into HeLa cells. 
106 
Organosolv 
lignin 
(Spherical)  
Ultrasonication 
The curcumin-loaded LNPs showed an improved bioavailability after 
oral administration compared to the free curcumin, which can be 
ascribed to the enhanced curcumin solubility and stability, sustained 
release and superior intestinal permeability and consequent its 
absorption, as well as the inhibition of P-gp mediated efflux. 
107 
Different Lignin 
sources  
(Nanotubes) 
Polymerization Vehicles for gene delivery and transfection with HeLa cells. 108 
Tissue Engineering  
Kraft lignin  
(Scaffold 
fibers) 
Electrospinning 
The incorporation of 10 wt-% lignin in the lignin-PCL composites 
resulted in a minimum fiber diameter and optimal pore size, along with 
an enhanced mechanical, physical, and morphological properties 
109 
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compared with pure PCL, making the lignin-PCL promising for tissue 
regeneration applications. 
Alkylated lignin 
(Nanofibers) 
Polymerization 
and 
electrospinning 
The incorporation of lignin into the PLLA/PLA-lignin nanofibers 
increased their antioxidant activity, and showed good biocompatibility 
and induced higher cell proliferation (PC12, HDFs, and MSCs), 
relevant cell lines for tissue regeneration applications. 
91 
Enzymatic 
hydrolysis 
lignin 
(Aerogels) 
CO2 induced 
gelation and 
supercritical 
drying 
Stable calcium-crosslinked alginate–lignin aerogels were prepared, 
using up to 2:1 (w/w) alginate-to-lignin ratio. The resulting aerogels 
presented good cytocompatibility and cell adhesion, making them 
promising for tissue engineering and regenerative medicine.  
110 
Abbreviations: Ag: Silver; CLPs: Colloidal lignin particles; EbNPs: Environmentally benign lignin-core NPs; HDFs: Human dermal 
fibroblasts; LNPs: Lignin NPs; MSCs: Mesenchymal stem cell; PCL: Polycaprolactone; PCLLA: Poly(ε-caprolactone-co-lactide); 
PDAC: Polydiallyldimethylammonium chloride; P-gp: P-glycoprotein; PLA: Poly(lactic acid);  PLLA: Poly(ɩ-lactic acid); PVA: 
Poly(vinyl alcohol); SAS: Supercritical anti-solvent. 
 
 
Antioxidant compounds possess the ability to inhibit or scavenge free radicals in order to 
prevent oxidation, being particularly interesting for several industries, including 
pharmaceuticals, cosmetics, food, plastics, and oil fuel production.111–113 Originated from 
natural sources, lignin has the potential to replace synthetic antioxidant compounds, due to the 
biodegradability and low toxicity. Moreover, the abundance of hydroxy- and methoxy-groups 
in the lignin backbone prevents the oxidation propagation reactions by hydrogen donation, and 
acts as a stabilizer in reactions induced by oxygen and reactive oxygen species (ROS) to slow 
down the ageing process of different composites and biological systems.111,114,115 
Although raw lignin presents an inherent antioxidant property, the source of the lignin 
polymer can influence the scavenging ability, as demonstrated by Yearla and Padmasree 
(2016).71 In their study, the absorbance of 2,2-diphenyl-1-picrylhydrazyl (DPPH) radical at 517 
nm was measured to compare the antioxidant potential of softwood alkali lignin (AL) and 
hardwood dioxane lignin (DL). The AL showed higher DPPH scavenging ability than the DL, 
possibly owing to the higher guaiacyl content in the softwood AL, which presents higher 
antioxidant ability due to the ortho-methoxy substitution, as well as the lower carbohydrate 
contamination in AL compared to DL.71,116 Moreover, the AL and DL were nanosized to ALNPs 
and DLNPs, respectively, which increased even more their radical scavenging ability 
compared to the raw lignin polymers, showing the following order for the antioxidant potential: 
DLNPs > ALNPs > DL > AL.71 Additionally, the antioxidant activity was also dependent on the 
size of the LNPs, in which smaller NPs exhibited higher activity due to the better accessibility 
of phenolic hydroxyl groups to free radicals compared to the larger particles.99 
The UV-protective or absorbing properties of the lignin polymer is especially important in 
the formulation of sun protection lotions due to the excellent sunscreen performance by 
reducing the UV exposure, in particular the UVA and UVB transmittances. For example, Lee 
et al. (2019) prepared lignin-poly(vinyl alcohol) (PVA) nanocomposite fibers via electrospinning, 
with 50 and 85 wt-% lignin content.117 Both ratios of the lignin-PVA composites showed UV 
protection factors higher than 50, indicating an excellent UV protection of the nanocomposite 
fibers. This UV-blocking effect of lignin is ascribed to the different functional groups present in 
the lignin structure, such as phenols, ketones and other chromophores, being considered a 
natural broad-spectrum sun blocker.118,119 Additionally, Qian et al. (2015) verified that after 
incorporation of 2 or 10 wt-% lignin into a commercial sunscreen lotion made a sun protection 
factor (SPF) of 15 reach that of a SPF 30 or SPF 50, respectively.120 Therefore, lignin can be 
considered as a green alternative to substitute the synthetic sunscreen actives currently 
available in the market.  
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Lignin is also a source of natural antimicrobial compounds, in which the phenolic 
monomeric fragments of the lignin can inhibit several microorganisms, including E. coli, B. 
licheniformis, and S. cerevisiae.111,121 This inhibitory mechanism can be ascribed to the 
presence of the C-C double bond in the α- and β-positions of the side chain and a methyl group 
in the γ-position in the phenolic fragments, which are more inhibitory than the phenolic 
fragments containing functional groups with oxygen (e.g., –OH, –CO, and –COOH) in the side 
chain.111 Additionally, the intrinsic antimicrobial activity can also be correlated with the 
antioxidant property of the lignin, in which a higher antimicrobial effect of the lignin is related 
with a superior radical scavenging activity of the soluble lignin fractions.114,122 Additionally, 
silver (Ag+)-infused LNPs can also be prepared to potentiate the antibacterial effect of the Ag 
ions against Gram-positive and Gram-negative bacteria strains, using lower amounts of Ag to 
produce the same effect as the free Ag ions.77,102 This provides an environmentally friendly 
approach to replace the conventional metallic AgNPs, whose usage is limited by their high 
toxicity, persistence in nature, and negative effects related to their accumulation in water 
systems.77,123 
Pickering emulsions consist of emulsions stabilized by the presence of solid particles at 
oil–water interface, instead of using typical surfactants as stabilizers as in conventional 
emulsions.124,125 Compared to the conventional emulsions, Pickering emulsions can provide 
an increased stability against coalescence, biocompatibility and safety for in vivo purposes, as 
well as stimuli-responsiveness, being used in different fields, including biomedical, food and 
cosmetics.124 Generally, the mechanism for the stabilization in Pickering emulsions relies on 
the formation of a steric barrier at the oil–water interface, where the solid particles attach in an 
irreversible manner, providing an improved stabilization compared to the surfactant 
adsorption.124,125 However, the type of Pickering emulsion (oil-in-water or water-in-oil), the 
stability and morphology will depend on the properties of the solid particles, and the most 
commonly used particles are composed by silica, chitosan, magnetic NPs, nanotubes and 
cyclodextrin, among others.124 In addition to those, LNPs have been proposed as alternative 
to improve the stabilization of Pickering emulsions via steric and electrostatic repulsion.126 An 
effective stabilization will depend on the LNP properties, such as average size and size 
distribution, surface charge, wettability, LNP concentration, and presence of functional groups 
that allow the grafting onto lignin core or modification of LNPs with stimuli-responsive 
materials.103,126,127 
Finally, lignin has gained increased attention as a starting material to prepare a variety 
of LNPs and other lignin-based drug/gene delivery carriers (e.g., micro/nano-capsules, 
micro/nano-particles, and hydrogels) or tissue engineering and regeneration materials (e.g., 
hydrogels, scaffolds or nanofibers).7,128 As discussed in section 2.1.2, different methodologies 
and several parameters can be fine-tuned to develop lignin-based materials with suitable 
properties for the desired application. In particular, LNPs have recently emerged as a platform 
to deliver different compounds for cancer therapy, and the majority of the existing literature is 
mainly focused on in vitro anticancer studies, while the in vivo assessments are barely studied, 
with only few reports on the in vivo performance of LNPs.7,129 For example, Dai et al. (2017) 
evaluated the anticancer effect of resveratrol-loaded LNPs both in vitro and in vivo.105 In this 
study, the non-loaded NPs did not show adverse hemolysis effects or other side effects, while 
the resveratrol-loaded NPs showed a significant inhibition of tumor growth. 
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2.2 Nanomedicines for cancer therapy 
 
According to the World Health Organization (WHO), cancer consists of a group of the diseases 
with the highest incidence and mortality worldwide.8 Cancer is characterized by the 
uncontrolled division and growth of anomalous cells that ultimately can acquire the capacity to 
invade the surrounding tissues and spread to other organs.130 In 2018, there were 18.1 million 
new cases and 9.6 million deaths, and these numbers are expected to increase in the future 
to 20 million new cancer cases per year by 2025.8  
Currently, the cancer treatments rely on surgery to remove the tumor, and chemotherapy 
together with radiation to kill tumor cells that are more susceptible to these treatments due to 
their ability to divide and grow faster than healthy cells.131 A variety of chemotherapeutics have 
been mainly used to induce apoptosis, interfere with the cell cycle progression and gene 
transcription, and inhibit angiogenesis.131,132 Despite all the advances in the cancer treatment 
modalities during the recent years, most of the conventional chemotherapeutic drugs still lack 
efficiency to eradicate the cancer. These challenges are mainly due to the poor tumor-specific 
delivery and non-specific distribution of the drugs in the body, which can lead to appearance 
of systemic side effects caused by the high toxicity towards healthy cells, and low water 
solubility and therapeutic index of the chemotherapeutics.9 This will eventually induce 
multidrug resistance, defined as either a lack of tumor size reduction or the occurrence of 
clinical relapse after an initial positive response to antitumor treatment.10,11 Additionally, other 
therapeutic modalities have been investigated in order to answer the hallmarks of cancer that 
were established to rationalize and understand the complexity of this disease.133 The 
therapeutic approaches that target the hallmarks of cancer include the use of epidermal growth 
factor receptor (EGFR) inhibitors to sustain the proliferative signaling, immune activating anti- 
cytotoxic T-lymphocyte associated protein 4 (CTLA-4), monoclonal antibodies to avoid the 
immune destruction, and inhibitors of vascular endothelial growth factor (VEGF) signaling 
pathways that induce angiogenesis, among others.133  
Nanomedicines have emerged as innovative and promising alternative technologies with 
many advantages over the conventional therapies, providing new opportunities for early 
detection, diagnosis, and enhanced treatment of cancer.12 Moreover, these nanosystems can 
also be used to carry multiple therapeutic molecules for synergistic cancer therapy.134 
Additionally, theranostic platforms in cancer combine both diagnostic and therapeutic tools in 
a single formulation, offering the possibility to have an individualized treatment regimen (e.g., 
select the therapy and monitor the response to the treatment based on the specific molecular 
characteristics of the disease).135–137 In fact, nanoparticulate drug delivery systems have been 
utilized in clinical practice since the 1990's. Until 2016, over 25 nanomedicines were approved 
either by Food and Drug Administration (FDA) or European Medicines Agency (EMA), and 
other 45 nanoparticulate systems were at that time in ongoing clinical trials.138 Since 2016, 
another 3 nanomedicines were approved, and 18 new NPs have entered clinical trials, of which 
17 are indicated for cancer therapy.139 
Generally, the distinctive characteristics of cancer nanomedicines include: (i) 
biocompatibility; (ii) the ability to improve the pharmaceutical properties of the therapeutic 
molecules, such as stability, solubility and circulating half-life; (iii) co-deliver multiple drugs to 
improve their therapeutic efficiency and overcome drug resistance; (iv) deliver the payloads 
specifically to a certain cell or tissue, reducing their side effects; and (v) sustain or trigger the 
drug release upon a certain stimulus.9,13–15 The physicochemical properties of NPs, such as 
size, shape, charge, and surface chemistry can determine their biodistribution and in vivo 
biological interactions, upon a specific administration route (Figure 4).16 Therefore, it is 
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important to choose the NPs’ composition and tailor and design the NPs, according to their 
application and administration route to have the desired properties/effects. 
 
 
Figure 4. Parameters that should be considered when engineering nanoparticles, such as 
composition, charge, size and surface chemistry of the NPs, as well as the use of targeting 
ligands or stimuli-responsive materials. These parameters should be evaluated carefully 
according to the administration route, as they will affect the biodistribution of the nanoparticles 
after in vivo administration. Copyright © 2020 Elsevier B.V. Adapted and reprinted with 
permission from ref.16 
 
 
Administration route 
 
The abovementioned physicochemical properties of the nanocarriers impact their stability, 
delivery efficiency, and biodistribution upon administration. The delivery of NPs into the tumor 
is affected by several factors: NPs should (i) evade clearance by renal filtration and the 
reticuloendothelial system (RES); (ii) extravasate through the enlarged endothelial gaps in 
tumors; (iii) penetrate the compact stroma in the TME to reach the tumor cells; (iv) persist in 
the tumor tissue for a sustained period of time; and (v) release the therapeutic agents to induce 
their pharmacological effect.140–142 Therefore, the design of the NPs should be optimized and 
adjusted taking into consideration the tumor physiology and the administration route of the NPs 
for optimal delivery of the payloads.140,143,144 The delivery of nanocarriers to the tumor tissue in 
different animal species usually involves a systemic or local administration, where the most 
commonly used approaches are intravenous (i.v.),  intraperitoneal (i.p.), and intratumor (i.t.). 
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The local delivery of nanomedicines (e.g., i.t. injection) should be considered when the 
tumor site is accessible, avoiding the need of the EPR effect. Additionally, bypassing the 
systemic administration can also help to easily overcome other physiological barriers and 
achieve a better therapeutic effect at the tumor site, with reduced systemic toxicity, being a 
promising approach for tumors in the lung, bladder, brain and eye.145–148 Regarding the 
systemic administration of nanomedicines, the i.v. route of administration can be used to 
deliver the nanomedicines to the tumor tissue, and the NPs can benefit of the EPR effect in 
some solid tumors, which is responsible for the “passive targeting” of nanomedicines to the 
tumor site.149,150 Additionally, the i.p. administration of nanomedicines is an attractive strategy 
for the treatment of peritoneal carcinomatosis for different animal models.151 The peritoneal 
carcinomatosis is characterized by the attachment of cancer cells to the mesothelial layer on 
the peritoneal membrane, originating primary cancers in peritoneal cavity of certain organs, 
including ovary, liver, colon, pancreas and stomach.151,152 Delivering the nanomedicines by i.p. 
injection will retain the therapeutic agents as much as possible in the peritoneal cavity, 
maximizing the therapeutic efficiency and limiting the systemic side effects.151  
 
 
Composition 
 
The NP composition affects the biodistribution and stability, as well as the optical/magnetic 
properties. Nanomedicines can be classified as organic or “soft” NPs (e.g., polymeric and lipid-
based NPs), inorganic or “hard” NPs (e.g., silicon/silica NPs, gold NPs, iron oxide NPs, and 
carbon nanotubes), or biologically-derived nanoplatforms (e.g., cancer cell or red blood cell 
membrane-coated NPs).12,153,154 Additionally, the preparation of pure drug nanocrystals can 
also improve solubility and bioavailability of poorly water-soluble drugs.155 The main 
advantages and disadvantages of each nanosystem are summarized in Table 2. 
 
 
Size, shape, surface chemistry and charge 
 
In addition to the effect of the NP composition, the physicochemical properties of the 
nanomedicines (e.g., size, morphology, surface chemistry and charge) can also alter the 
cellular interaction and in vivo pharmacokinetics, such as biodistribution, cellular uptake, and 
half-life of NPs in the bloodstream after administration.156 
Regarding the NP size, smaller NPs (< 5.5 nm) tend to face a rapid renal filtration and 
consequent urinary excretion, while NPs larger than 200 nm can suffer from liver and spleen 
clearance, while particles or NP aggregates larger than 2 µm will accumulate in the lungs.156–
158 Consequently, the optimal NP size that shows an increased extravasation through the 
vasculature at the tumor and benefits of the EPR effect appears to range between 20 and 200 
nm.159 In addition to the influence on the in vivo fate of the NPs, the particle size also influence 
the pathway by which the NPs are internalized by different cells: (i) large particles are more 
likely to be internalized by phagocytosis; (ii) particles smaller than 1 μm can be taken up non-
specifically by micropinocytosis; and (iii) smaller particles (60–200 nm) can be internalized 
using different mechanisms, such as clathrin- and caveolin-mediated endocytosis or clathrin- 
and caveolin-independent endocytosis.160–162  
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Table 2. Summary of the main advantages and disadvantages of different nanosystems, 
based on their composition. 
Type of 
Nanosystem 
Advantages Disadvantages Ref. 
Drug nanocrystals 
 
 100% drug (no carrier); 
 Crystalline or amorphous structure 
(amorphous state offers advantages); 
 Increased solubility and dissolution rate; 
 Increased solubility; 
 Increased adhesiveness to surface/cell 
membranes; 
 Increased bioavailability of the drug. 
 Generally needed to be 
stabilized by surface active 
agent; 
 Possible nanotoxicity and 
side effects. 
155 
Organic/“Soft” NPs   
Polymeric-based 
NPs 
 
 Tunable size, shape, and surface 
properties, and easy functionalization; 
 Biocompatibility; 
 Good stability; 
 Encapsulation of both hydrophilic and 
hydrophobic agents; 
 Possible to use stimuli-responsive polymers; 
 Drug release in a controlled and sustained 
manner; 
 Promote humoral and cellular responses. 
 Difficult to scale-up; 
 Difficult purification 
methods; 
 Poor storage conditions. 
163–168 
Lipid-based NPs 
 
 Ability to entrap hydrophobic and hydrophilic 
chemotherapeutic and imaging agents; 
 Good stability in biological environments; 
 Drug controllable release kinetics; 
 Biocompatibility; 
 Allow surface functionalization. 
 Short-circulating properties 
(if not functionalized); 
 Difficult purification 
methods; 
 Poor encapsulation of 
hydrophilic drugs. 
169–172 
Inorganic/“Hard” NPs   
Mesoporous 
Silica/Silicon NPs 
 
 High loading degree; 
 High porosity; 
 Allow surface functionalization; 
 Biocompatibility; 
 Biodegradability; 
 Intrinsic adjuvant property. 
 Short circulation time (if not 
functionalized); 
 Poor stability in physiologic 
conditions. 
173–177 
Gold NPs 
 
 
 Bioinert; 
 Tunable size and shape, and it can be 
functionalized with drugs and other ligands; 
 Easy penetration and accumulation at the 
tumor sites; 
 Optical properties (for photothermal therapy 
and photoimaging). 
 Nonbiodegradable; 
 Long-term toxicity. 
178–180 
Iron oxide NPs 
 
 
 Chemically inert; 
 Low toxicity; 
 Easy tunable surface properties and 
functionalization; 
 Superparamagnetic behavior (for magnetic 
resonance imaging); 
 Hyperthermia agents; 
 Contrast agents for computed tomography. 
 Limited colloidal stability (if 
their surface is not coated); 
 High opsonization by 
macrophages. 
181–183 
Carbon nanotubes 
 
 Unique structures; 
 Easy functionalization; 
 Large surface area; 
 Optical properties (for photothermal therapy 
and photodynamic therapy). 
 Long-term cytotoxicity (if 
not functionalized); 
 Lack of size uniformity 
during the synthesis process. 
184–186 
Biologically-derived NPs   
Cancer cell 
membrane-coated 
NPs 
 
 
 Long-circulating properties; 
 Surface antigenic source;  
 Stimulate both cell-mediated and humoral 
immune responses. 
 Poor colloidal stability; 
 Difficulty of loading 
proteins. 
187–189 
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As for the surface charge, positively charged NPs tend to interact to a higher extent with 
the negatively charged components on the cell membrane via electrostatic attractions, 
compared to the negatively charged or neutral counterparts.161,190 Furthermore, the cationic 
particles take advantage of their charge to facilitate endosomal escape through the ‘proton 
sponge effect’, avoiding the premature release or degradation of the payloads in the 
endosomal compartment.191 However, cationic NPs can also cause cytotoxicity due to the 
increased mitochondrial and lysosomal damage, and disruption of plasma membrane integrity, 
compared to the anionic counterparts.190 In order to overcome this limitation, zwitterionic NPs 
can be tailored to have a balance between negative and positive charges on their surface in 
order to accomplish simultaneously an enhanced cellular uptake and cytocompatibility.161 
Although the spherical shape of NPs is the most widely studied morphology, different 
shapes have also been developed, such as cylinders or rod-like, prisms, worms, branched 
structures, or cubes, and their interaction with cells and the hemorheological dynamics have 
been evaluated.156,161,192,193 During the circulation in the bloodstream, rod-like particles exhibit 
increased predisposition of NP–cell wall contact and possible extravasation through 
fenestrations in vasculature compared to the spherical counterparts.156,194 In addition, the ratio 
between the height and width of the particle, i.e., the aspect ratio, also affects the cellular 
uptake rate. Here, the rod-like particles (higher aspect ratio) exhibit an enhanced 
internalization than the spherical particles (low aspect ratio), because of the higher contact 
area with the cell membrane.195  
Flexibility/elasticity, hydrophilicity/hydrophobicity and roughness are other parameters 
that influence the biodistribution, cell internalization, cytocompatibility and also immunogenicity 
of the NPs. In accordance with the film-tension model, NPs that are more hydrophobic than 
the cell surface tend to be more internalized than the ones that are more hydrophilic.196 
Conversely, hydrophobic NPs are more prone to aggregate and, consequently, removed from 
the bloodstream by the mononuclear phagocyte system (MPS).197 In order to overcome this 
problem, the coating of the NP surface with PEG provides hydrophilicity and a hydrated cloud 
to the nanocarrier that sterically prevents the NPs from interacting with blood components and 
extends their circulating half-life.198  
The elasticity of NPs, defined by Young’s or elasticity modulus, can also regulate the 
circulation of the NPs in the bloodstream and, consequently, their accumulation at the tumor 
tissue due to the ability of the NPs to interact with the cell surface receptors and being 
internalized. In this regard, softer or low-flexible NPs are more taken-up by the cells than the 
stiffer or high-flexible NPs.199,200 Additionally, the elasticity/flexibility can also direct the uptake 
mechanism of the NPs by the cells: (i) soft NPs are more internalized through micropinocytosis; 
(ii) an intermediate Young’s modulus can drive the NPs to be internalized using multiple uptake 
mechanisms; and (iii) stiff particles are more likely taken-up via the clathrin-mediated 
mechanism.201  
Overall, the different parameters of the NPs, and respective outcomes on the NP 
biodistribution and cellular uptake upon administration are summarized in Table 3.16 
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Table 3. Influence of the physicochemical properties of NPs in the biodistribution and cellular 
uptake. Adapted and reprinted with permission from ref.16 
Parameter Outcome 
Size  
< 6 nm  Undergo kidney by renal clearance after i.v. administration. 
20–200 nm 
 Increased extravasation through vascular fenestrations of tumors (via the EPR effect); 
 Increased ability to cross the gastrointestinal barrier and blood-brain barrier; 
 Optimal size for passive targeting of the injured left ventricle. 
> 200 nm  Increased entrapment within the liver and spleen. 
2–5 µm  Accumulation in the lungs. 
Charge  
Anionic  Moderated circulating half-life. 
Neutral  Moderated circulating half-life. 
Zwitterionic  Moderated circulating half-life. 
Cationic 
 Rapid clearance from circulation; 
 Higher interaction with the negatively charged cell membranes; 
 Facilitated endosomal escape via ‘proton sponge effect’. 
Shape  
Spherical  Induce less cytotoxicity, compared to the fiber-shaped particles. 
Rod-like 
 Prolonged circulation time, compared to the spherical NPs; 
 Improved ability to marginate and drift towards the vessel walls, increasing their 
interaction with the endothelial cells and consequent extravasation through the 
vasculature. 
Discoidal  
 Increased tendency for the NP–cell wall interaction and potential extravasation 
through the vascular fenestrations. 
Chemistry  
Hydrophilicity  Prolonged circulating half-life. 
Hydrophobicity 
 Increased cellular uptake; 
 Induce more cytotoxicity than the hydrophilic surfaces. 
Flexibility/Elasticity 
 Higher internalization of softer particles by different cell lines, compared with the 
stiffer particles. 
Roughness 
 Improved loading capacity of therapeutics; 
 Enhanced cellular uptake. 
 
 
2.3 Biological barriers encountered by nanomedicines 
 
Generally, nanomedicines come across several biological barriers upon administration, before 
they reach the tumor, after which they experience other obstacles at cellular and intracellular 
level.12 By understanding the physiology and architecture of the tumors (e.g., density and 
extracellular matrix organization), other properties of nanomedicines can be tailored to 
increase their accumulation in the tumor site, including passive targeting (driven by the EPR 
effect), active targeting of nanomedicines decorated with targeting ligands, and also the use 
of stimuli-responsive materials that allow the release of the therapeutic cargos at a specific site 
under certain stimulus.145,202,203 Additionally, the nanomedicines can be modified to decrease 
the protein adsorption after administration and, therefore, prevent their opsonization and rapid 
clearance from the blood stream.145 These different approaches will be addressed in the 
following sections. 
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2.3.1 Protein corona formation, opsonization and clearance of nanomedicines 
 
Besides the red blood cells, the bloodstream contains plenty of small molecules, such as 
proteins, peptides, lipids, sugars and complexes of these molecules. When NPs reach the 
bloodstream upon administration, the NP surface can be covered by the abovementioned 
molecules, which will modulate the NP interaction with the different tissues and alter their 
fate.204 This adsorption of biomolecules (usually small proteins) onto the NP surface is a 
phenomenon known as “protein corona” formation, which was first proposed in 2007 and 
derived from the concept of “protein adsorption” in different materials initially described in the 
1950s and 1960s.205–208 The protein corona can be defined by the existence of two distinct 
layers adsorbed onto the NP surface: (i) the “hard corona” constituted by proteins with high 
affinity that may be irreversibly bound onto the NP surface, and (ii) a “soft corona” composed 
by a second protein layer with low affinity to the chemical moieties on the NP surface that are 
adhered through reversible interactions.204,209 Among other important parameters, the 
formation of the protein corona will alter the original NPs composition, leading to the reduction 
in their stealth effect, targeting ability of the NPs to recognize specific receptors in the target 
tissue, and consequent reduction in cell internalization, which then translates into a poor 
therapeutic efficiency of their cargos.208,210 Additionally, the opsonin molecules (e.g., proteins, 
immunoglobulin (Ig) G or complement factors) present in the bloodstream can also bind to the 
NP surface, which leads to the recognition, phagocytosis and clearance of the NPs from the 
systemic circulation by the macrophages of the MPS, usually liver Kupffer cells and splenic 
macrophages, a process known as opsonization.197,211,212 The circulation time of the NPs in the 
bloodstream is also dependent on the nature of the molecules that bind to the NP surface. 
When high amounts of dysopsonins (i.e., molecules that slow down the phagocytosis process, 
such as apolipoproteins and albumin) are part of the protein corona, the NPs are retained in 
the blood circulation for longer times than the ones with opsonin proteins in their surface.213,214  
The interaction of proteins with NPs will also depend on the physicochemical properties 
of the NPs, including the composition, size, hydrophobicity, surface charge and chemistry, and 
shape, but also on the characteristics of the physiological environment in which the NPs are 
exposed, such as the composition, pH, and temperature of the media, the duration of exposure, 
as well as the dynamic shear stresses in the body.210,214 Therefore, modulating the surface 
properties of the NPs by coating them with stealth polymers, such as PEG or 
polyvinylpyrrolidone (PVP), can prevent the NPs from aggregation and opsonization, and help 
to escape from the MPS.215,216 Consequently, there is an increased circulation time of the NPs 
in the bloodstream and improved delivery of their therapeutic compounds to the target 
tissue.214 Besides the reduced protein adsorption, PEGylation also allows the NPs to adsorb 
distinct proteins that were found to be necessary for the stealth effect and prevent non-specific 
cellular uptake of the PEGylated NPs, such as apolipoprotein J.217,218 In addition, parameters 
such as the molecular weight, length, conformation, and the density of PEG on the NP surface 
affect the circulation time in the bloodstream.219 For example, increasing the molecular weight 
of the PEG used to cover the NP surface leads to an increase in the circulation time and 
decrease on the protein adsorption onto the NP surface.220,221  
Although the protein corona formation was initially seen as an obstacle that interferes 
with the NP stability and prevents NPs to reach their target tissue, this phenomenon is now 
seen as a tool to modify the NP surface in order to develop nanomedicines with better 
therapeutic effect and diagnosis ability. More recently, the concept of the protein corona has 
been evolved to the one of “biomolecule corona”, which also contains several types of 
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biomolecules that are part of the corona, and this is explored for targeting, diagnosis and also 
drug delivery purposes.208 
 
 
2.3.2 Extravasation and accumulation of nanomedicines at the tumor 
 
Nanomedicines can be tuned and benefit from different strategies in order to increase their 
accumulation in the tumor site, and also the therapeutic efficiency of their payloads. These 
approaches are generally divided into passive and/or active targeting of nanomedicines, and 
the use of stimuli-responsive materials that allow the release of the payloads upon a certain 
internal or external trigger (Figure 5).14,222  
 
 
Figure 5. Mechanisms/approaches to deliver chemotherapeutics into tumors: A) Passive 
targeting that exploit the EPR effect mediated through leaky tumor vessels; B) active targeting 
of nanoparticles functionalized targeting ligands that specifically bind to receptors on the tumor 
cell’s surface; and C) use of stimuli-responsive materials that release the chemotherapeutic 
upon an external or internal stimuli. Copyright © 2019 Nature Publishing Group. Adapted and 
reprinted with permission from ref.222 
 
Enhanced permeability and retention effect in passive targeting  
 
The EPR effect was first described in 1986 by Matsumura and Maeda,223 and it is based on 
the pathophysiological and anatomical characteristics of some solid tumors and their 
microenvironment compared to the healthy tissues, which allows a preferential accumulation 
of the nanomedicines in the tumor.224,225 The passive targeting of NPs is based on the EPR 
effect, along with the modifications on the NP surface to prolong the circulation time in the 
bloodstream.135 The EPR effect on the passive targeting of NPs is due to the abnormal and 
large fenestrations in the blood vessels present in the TME, usually between 100 and 780 nm, 
that allows the extravasation of nanomaterials with sizes up to several hundreds of nanometers. 
Additionally, the extensive angiogenesis and lack of lymphatic drainage also promote the 
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retention of nanomedicines in the tumor vicinity.224,225 The density of the extracellular matrix 
components in the TME, such as hyaluronic acid and collagen, can also limit the penetration 
of the NPs from the blood vessels deep into the tumor tissue. The TME is also composed by 
stromal cells, which include pericytes, fibroblasts, endothelial cells, macrophages, dendritic 
cells, among other immune cells, that also affect to the EPR effect and limit the diffusion of 
NPs into to tumor cells.14,224 Moreover, there are some other challenges regarding the 
heterogeneity within and between the different types of solid tumors, such as: (i) the 
dimensions in the vasculature fenestrations can change with the tumor location (i.e., primary 
tumor versus metastases); (ii) distinct vessel structures within a single tumor type; and (iii) the 
extent of macrophage infiltration and the activity of the MPS that can vary within and between 
tumors.226,227 Additionally, the EPR effect does not direct the end result upon in vivo 
administration of nanomedicines. The events after the delivery of NPs or macromolecules to 
tumor tissues through the EPR effect also control the true therapeutic outcome.149 The 
development of a next-generation of nanomedicines with targeting ligands and/or stimuli-
responsive materials is needed to overcome the abovementioned issues and improve the 
accumulation of the nanomedicines at the tumor tissue.  
 
 
Active targeting strategies 
 
A second generation of nanomedicines has emerged to improve the properties of the NPs and 
overcome the limitations of the EPR effect and complement the passive targeting of NPs. For 
that, the nanosystems can be decorated with targeting ligands that allow the NPs to bind 
specifically to a certain cell receptor after extravasation, increasing their cell internalization and, 
consequently, improving the efficacy of the therapeutic compounds while minimizing their side 
effects.9,17,18 Generally, targeting approaches take advantage of the differential expression of 
certain receptors between healthy and tumor cells. The most commonly used ligands are 
proteins, antibodies, peptides, nucleic acids (aptamers), polysaccharides (hyaluronic acid), 
among other small molecules.228–230 The NP surface can be functionalized with the different 
targeting moieties using different approaches, such as chemical/covalent conjugation or 
physical adsorption on the NPs after the preparation, or linked to the NP functional groups 
before the formation of the NPs.17 Among all the biological ligands, peptides have been most 
widely used for actively targeting nanomedicines and delivering anticancer drugs to the tumor 
tissue.231,232 Short tumor-penetrating peptides offer certain advantages over other targeting 
ligands, such as other small molecules and larger antibodies, including small size, high 
specificity and affinity, increased tissue penetration, easiness to synthesize, and non-
immunogenic nature.231,232 Tumor homing peptides are usually identified using a 
bacteriophage (phage) display, which is a technique that allows the screening of different 
peptides in order to design and select the peptide sequences that show higher affinity to the 
specific target and respective hydrophobic binding pocket.232,233 Briefly, the phage display 
technique is a cyclic process that relies on the incubation of the purified target molecules with 
a randomized peptide sequences library displayed on bacteriophage capsids. Afterwards, non-
specific peptides are washed away, allowing the selection of high affinity peptides displayed 
on the bacteriophages, which are then eluted, collected, and seeded on a plate to infect E. coli, 
before amplification and new cycle of selection. Up to five rounds of biopanning, i.e., affinity 
selection, are needed in order to identify the peptides that bind to the target with high 
affinity.233,234 This technique has allowed the discovery of a large number of tumor-homing 
peptides that have been used as tools for imaging and therapy.235,236  
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The most widely used peptide that specifically recognizes and extravasates through the 
endothelial cells of tumor blood vessels, and penetrate into the tumor tissue, is the iRGD 
(CRGDKGPDC). This peptide contains an integrin-binding RGD motif that specifically binds at 
a first stage to αv-integrins that are selectively expressed on several tumor cells, which then 
binds to the neuropilin-1 (NRP-1) receptor upon a proteolytic processing of the iRGD, 
improving the tumor penetration.237 This class of tumor-penetrating peptides requires the C-
terminal exposure of the C-end rule (CendR) motif (R/KXXR/K), which then binds to the CendR 
NRP-1 receptor. Other classes of tumor-penetrating peptides have also been identified by 
phage display, such as the smaller peptides constructed from tumor-homing motifs or CendR 
elements.237 Although they offer a solution for the drug penetration issue into the tumors, these 
peptides have usually a very short half-life upon administration (few minutes). This can be 
explained by enzymatic degradation and rapid renal clearance and elimination into the 
urine.237,238 One way to overcome this problem is to attach the peptides on the surface of drug-
loaded NPs, with increased therapeutic efficiency of the payloads.239,240 Additionally, the ligand 
density on the NP surface is an important parameter to achieve the most efficient delivery of 
the therapeutics, which can differ in in vitro and in vivo circumstances, mainly due to the 
abovementioned biological barriers.241 It is expected that at a high ligand density, the chances 
of improved binding of NPs to the target are more likely to happen. However, the high ligand 
density can raise some issues, such as: (i) increased NP average size after functionalization 
can decrease the accumulation in the tumor through the EPR effect; (ii) high conjugation 
efficiencies of the targeting moieties can be responsible for the decreased stealth properties 
of the NPs due to the reduced presentation of antifouling agents at the NP surface, promoting 
their rapid clearance from the bloodstream; (iii) the steric hindrance derived from the presence 
of high ligand amounts can lead to a diminished binding of NPs to their target; and (iv) the 
binding of NPs to a high number of cell surface receptors can reduce the overall cell 
internalization.241 Another aspect to consider is the nanomedicine stability to avoid premature 
drug release and degradation in the bloodstream, which can be improved by developing 
stimuli-responsive materials.  
 
 
Stimuli-responsive approaches 
 
This generation of nanomedicines relies on the use of  stimuli-responsive materials to enhance 
even further the therapeutic efficacy and biological specificity of the therapeutic compounds, 
by releasing the drug upon exposure to a certain stimuli and, therefore, minimizing the systemic 
side effects of these compounds.242,243 Different triggers can be used to promote the drug 
delivery in a temporal-, spatial-, and dosage-controlled manner, and these can be (i) 
endogenous stimuli, such as enzyme concentration, pH changes in the body compartments, 
and redox gradients; (ii) exogenous stimuli, including magnetic field, temperature variation, 
ultrasound intensity, and light pulses; and (iii) multi-stimuli triggered drug release.135,243,244 
Regarding the endogenous triggers, the fact that some solid tumors exhibit a more acidic 
microenvironment (pH 5.5–7.2) than the physiological pH in the blood and healthy tissues (pH 
7.2–7.4) can be exploited to deliver drugs specifically to a tumor tissue.135,245 Different 
approaches can be done to develop pH-responsive nanomedicines for cancer therapy, such 
as pH-sensitive polymers that include histidine-, sulfonamide-, and tertiary amine-containing 
groups, or by including pH-sensitive chemical bonds that are stable at physiological pH but are 
hydrolyzed under the acidic TME conditions.245–247 The differential redox potential in tumor cells 
compared to the healthy tissues is another approach to selectively deliver drugs to the tumor 
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cells. Generally, reductive agents, such as glutathione (GSH), are present in the TME at higher 
levels compared to normal cells, which can be used to develop redox-responsive nanosystems, 
containing disulfide bonds or other GSH-sensitive crosslinking agents that are more prone to 
be cleaved by GSH.243,248 Enzyme-mediated drug release relies on the altered expression 
profile of certain enzymes, such as phospoholipases, glycosidases or matrix 
metalloproteinases. This controlled drug release can be mediated be the use of short peptide 
sequences that are prone to be cleaved by these enzymes, allowing a more effective drug 
accumulation in the tumor site.249,250  
An example of exogenous stimuli-sensitive materials is a thermo-responsive 
nanosystem that benefits from an induced local hyperthermia in the tumor compared to the 
surrounding temperature, increasing the vascular permeability at the tumor tissue and allowing 
the drug release. Preferably, thermo-responsive materials should be designed so that their 
payloads are not released at body temperature (~37 °C), and delivered in the tumor at higher 
temperatures (~39–43 °C). There are a variety of nanosystems described in the literature that 
can be used for this purpose, including magnetic and superparamagnetic iron oxide NPs, gold 
NPs, and thermo-responsive polymers (e.g., PNIPAAm) that are used to develop different 
types of NPs or hydrogels.251,252 Magnetic-sensitive NPs can also enable the transport of the 
drug to the tumor tissue upon exposure to a permanent and/or alternating magnetic field. Iron 
oxide NPs, such as magnetite (Fe3O4) or maghemite (γ-Fe2O3), have been extensively 
exploited for the fabrication of these magnetically responsive systems, mainly due to their 
relatively low toxicity and high saturation magnetization, and they can also be loaded into a 
variety of colloidal nanosystems that will release the drug and become sensitive to the external 
magnetic field exposure.253,254 Other non-invasive and effective strategies to spatiotemporally 
release the drugs and contrast agents at the tumor site are based on the use of ultrasound, or 
photo-responsive materials that can react to different wavelengths (e.g., ultraviolet, visible, or 
near-infrared regions).243,255 
Additionally, the combination of different stimuli-responsive approaches gives the 
possibility to integrate both imaging and therapeutic modalities into a single platform for 
theranostic applications, allowing the real-time monitoring and assessment of the in vivo 
therapeutic efficacy of the drugs.135  
 
 
2.4 Nanotechnology and cancer immunotherapy 
 
Cancer immunotherapy represents a prominent class of treatments that exploits and boosts 
the immune system to fight tumors, and it shows several advantages compared to the other 
conventional treatments: (i) allows the immune system to specifically target and recognize the 
cancer cells, minimizing the side effects on healthy cells; (ii) can eradicate residual diseased 
cells and metastasis by the immune system, reducing cancer recurrence; (iii) can prevent 
cancer recurrence by generating immune memory, and (iv) the administration of cancer 
vaccines allows a prophylactic action against tumor cells.256 Generally, cancer 
immunotherapies are based on the lymphocyte activating cytokines (e.g., interferon (IFN)-α 
and interleukin (IL)-2), immune checkpoint inhibitors (e.g., anti-CTLA-4 and anti-programmed 
death-1 (anti-PD-1) monoclonal antibodies), adoptive cellular therapies (e.g., ex vivo 
expansion of tumor infiltrating lymphocytes, or chimeric antigen receptor (CAR) T cell therapy), 
oncolytic viruses, and cancer vaccines.222,256 Despite these improvements and innovations in 
cancer therapy, the use of immunotherapies still encounters some limitations related to their 
high cost, non-specific toxicity and lack of efficacy. Nanotechnology has appeared as a tool to 
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make immunotherapies less toxic and more effective, while facilitating the combination of 
current chemo- and immune-therapies for synergistic purposes.257–260 More specifically, 
nanosystems have been extensively engineered either to act as adjuvants in cancer vaccines, 
or as delivery systems of antigens and adjuvants.257,261 Nanocarriers present intrinsic 
advantages that enable their application in immunotherapy, including tunable size that allows 
the delivery of different compound to the lymphoid organs; the ability to carry antigens and 
adjuvants to mimic pathogens and increase their immunogenicity; and lastly the uptake of NPs 
by APCs leads to an increased cross presentation of antigens on major histocompatibility 
complex class I (MHC I) to the cytotoxic T cells (CTLs).19  
Among other modalities, TAMs-based therapies have also emerged as a promising 
target for cancer immunotherapy, due to the dominant presence of TAMs in the TME of certain 
tumors, and their phenotypic plasticity that enables their polarization towards an anti-tumor 
and pro-inflammatory subtype, also known as M1-like macrophages.20,21 
 
 
2.4.1 Role of tumor associated macrophages in cancer progression 
 
Solid tumors are composed by a complex environment that involves the interaction of tumor 
cells with the extracellular matrix components and stromal cells in the TME.262 Among other 
stromal cells in the TME, macrophages represent one of the most common inflammatory cells 
that make-up the tumor mass, and they can contribute up to 50% of the overall tumor mass.263 
Regarding their origin, TAMs can be derived from circulating monocyte precursors that are 
recruited to the tumor tissue in response to the chemotactic signals released by cancer cells, 
or they may originate from bone-marrow progenitors that are later differentiated into mature 
cells after seeding in the tumor tissues and partially maintained via self-renewal.263–265 Usually 
correlated with a poor outcome in most of the solid tumors, TAMs can be responsible for tumor 
growth and promotion by facilitating angiogenesis and immunosuppression, inhibiting T cell 
activation, tumor relapse after conventional cancer treatments, and tumor invasion and 
metastasis. This “communication” of TAMs with the tumor cells is done by releasing certain 
growth factors, cytokines and chemokines, in the TME that ultimately leads to the tumor 
progression and inhibits anti-tumor immune response (Figure 6).263,266,267  
Macrophages are generally classified into 2 groups: (1) the “classically activated M1”, 
which typically requires IFN-γ and/or lipopolysaccharide (LPS) for their polarization, and (2) 
the “alternatively activated M2” that involves the stimulation with IL-4 and/or IL-13. After their 
differentiation, they can be distinguished by the changes in gene and cell surface markers 
expression, and also by the consequent activation of different signaling pathways.263,268 On 
one hand, TAMs in progressing tumors present an immunosuppressive phenotype that 
resemble the “alternatively activated M2”, which usually express distinctive cell surface 
markers, such as CD163, CD204, and mannose receptor (CD206), and lead to the increased 
production of anti-inflammatory signals, including IL-10 and transforming growth factor (TGF)-
β, and also arginase 1 (ARG 1).266,269 On the other hand, TAMs with an anti-tumor phenotype 
resemble M1-like (or “classically activated”) macrophages, which are characterized by the 
expression of MHC II, CD68, CD80, and CD86 cell surface markers, the release of pro-
inflammatory cytokines, including IL-12, IL-1β, IL-6 and tumor necrosis factor (TNF)-α, and 
production of inducible nitric oxide synthase (iNOS, NOS2).263,269,270 
Although this is an oversimplification of the complexity of the different phenotypes and 
composition of TAMs, which can fluctuate between tumor stage and type of cancer, this 
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plasticity property of the macrophages that are able to go from a pro-tumor phenotype to an 
anti-tumor phenotype has been recently explored as a therapeutic target in cancer therapy.20  
 
 
Figure 6. Role of M2-like TAMs in tumor progression, invasion and metastasis and possible 
therapeutic targets/options (red lines).  
 
 
2.4.2 Tumor associated macrophages as a therapeutic target 
 
As a result of the reasons previously explained, TAMs have become an interesting therapeutic 
target in cancer therapy, and the emerging therapeutic strategies are: (i) inhibition of the 
monocytes/macrophages recruitment to the tumor tissue; (ii) blockade or depletion of TAMs; 
and (iii) repolarization of TAMs from their pro-tumor M2-like phenotype to an anti-tumor M1-
like phenotype (Figure 6).20,271–273  
The first mentioned strategy is to block the monocyte infiltration into the tumor tissue, 
which is usually done through the secretion of chemoattractant signals by the TME, such as 
colony-stimulating factor 1 (CSF-1, or M-CSF), VEGF, CCL2 and CCL5.20,263,274 The release 
of CSF-1 is responsible for controlling the proliferation, differentiation, survival and recruitment 
of monocytes and macrophages, and blocking the CSF-1 receptor signaling pathway leads to 
a decreased accumulation of immunosuppressive and pro-tumorigenic M2-like macrophages 
at the tumor.275,276 The CCL2 is one of the main responsible for recruiting classical monocytes 
from bone marrow to bloodstream, because CC-chemokine receptor 2+ monocytes are the 
main precursors of M2-polarized TAMs and, therefore, the CCL2-CCR2 signaling inhibits the 
recruitment of inflammatory monocytes and prevents metastasis in vivo.277 
Another approach is to selectively eliminate or deplete TAMs at the tumor tissue in order 
to trigger their apoptosis and, consequently, block the signal network that leads to the tumor 
growth. Different drugs can induce TAMs apoptosis and delay the tumor progression, but this 
approach usually brings severe side effects (e.g., bacterial infections), by systemically 
depleting other macrophages and other immunoprotective cells.20,263  
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One way to circumvent the drawback of TAMs depletion therapies is to take advantage 
of the macrophage plasticity, and use therapeutic modalities that revert their anti-tumor M2-
like phenotype towards a tumoricidal M1-like phenotype of TAMs after manipulating the 
environmental stimuli.20,263,272,273,278 
An overview of the current drugs and their respective targets used in the TAMs-based 
therapeutic approaches are presented in Table 4. Additionally, different nanoparticulate 
systems have been engineered to carry these drugs and effectively target them to the TAMs 
at the tumor site, or then to “take a ride” using macrophages as drug delivery carriers, because 
of their ability to migrate and infiltrate into tumors.279,280 
 
Table 4. Some examples of the TAMs-based therapeutic strategies.  
Therapeutic approach Drugs (Type) Target Ref. 
Inhibition of monocytes 
recruitment 
Carlumab (Antibody) CCL2 281 
PF-04136309 (Small molecule) CCR2 282 
TAMs depletion  
Alendronate (Bisphosphonate) Phagocytes 283 
Trabectedin (Small molecule) Caspase 8 284 
AMG 820 (Antibody) CSF-1R 285 
RG7155 (Antibody) CSF-1R 275 
JNJ-40346527 (Small molecule) CSF-1R 286 
Reprogramming M2-like 
towards an M1-like TAMs 
CC-90002 (Ab) CD47 287 
HPA063793 (Antibody) MARCO 288 
 CP-870,893 (Agonistic Antibody) CD40 289 
R848 (Small molecule) TLR 7/8 290 
IMO-2055 (Small molecule) TLR 9 291 
 
 
As these strategies to target TAMs act upstream of T cell responses, they might be useful 
to complement other immunotherapies that regulate T cells, such as the use of immune 
checkpoint inhibitors or adoptive cell therapies.267 Therefore, the combination of different 
anticancer treatment modalities simultaneously seems to improve the therapeutic efficiency 
and overcome the limitations of the individualized treatments.  
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3 Aims of the study 
 
Nanosystems with different compositions have been widely studied for cancer therapy and 
imaging during the past decades. The main aim of this thesis was to evaluate the potential of 
underexplored and innovative LNPs as platforms to deliver therapeutics for enhanced cancer 
therapy. In addition, the cytocompatibility and cell-NP interactions of bare and functionalized 
nanoparticles were investigated, and their biodistribution and therapeutic efficacy were also 
assessed. 
 
 
More specifically, the objectives of the present study were: 
 
1. To investigate the cytocompatibility of different lignin-based NPs towards several cell 
lines, and to evaluate the drug loading ability into the LNPs (I). 
 
2. To prepare carboxylated lignin to allow the preparation of LNPs functionalized with 
polymers and different targeting ligands (II). 
 
3. To surface modify the LNPs with DSS peptide and compare the cellular internalization 
with iRGD-functionalized LNPs, using 2D- and 3D-cell culture models (III). 
 
4. To functionalize resiquimod (R848)-loaded LNPs with mUNO peptide to target M2 
macrophages, to study their tumor-homing ability, and to assess repolarization of M2-
like phenotype into M1-like macrophages for synergetic chemotherapy (IV). 
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4 Experimental 
 
This section summarizes the experimental methods used for the studies described in the thesis. 
Detailed description of the materials, instrumentation and methods can be found in the original 
publications (I–IV). The preparation of oleic acid-coated Fe3O4 NPs and iron(III)-complexed 
LNPs (I) was done at Aalto University, Finland. The in vivo studies presented in publication IV 
were performed in collaboration with the Laboratory of Cancer Biology, University of Tartu, 
Estonia. 
The detailed description of the materials used in this thesis can be found in the materials 
and methods section of each original publication. 
 
 
4.1 Synthesis of carboxylated lignin (II–IV) 
 
The carboxylation reaction of the original lignin was done to increase the amount of carboxyl 
groups on the lignin for further conjugation reactions. In this thesis, the softwood kraft lignin 
used was obtained using two different technologies: LignoBoost™ and UPM BioPiva™. 
 
 
4.1.1 Carboxylation of LignoBoost™ softwood kraft lignin (II) 
 
Here, 100 mg of LignoBoost™ softwood kraft lignin was reacted with succinic anhydride (100 
mg, 21.2 mmol) and 4-dimethylaminopyridine (DMAP; 20 mg, 4.1 mmol) in 40 mL of THF at 
room temperature (RT) for 48 h.292 The reaction mixture was dialyzed against MilliQ-water, 
using a dialysis bag (Spectra/Por® 1 Standard RC Dry Dialysis Tubing, 12–14 kDa, Spectrum 
Labs, CA, USA) for 48 h to remove the unreacted reagents, changing the water periodically. 
Finally, the carboxylated lignin was freeze-dried and characterized with a Fourier transform 
infrared (FTIR) spectroscopy instrument (Vertex 70, Bruker, MA, USA), using a horizontal 
attenuated total reflectance (ATR) accessory (MIRacle, PIKE Technologies, WI, USA). The 
ATRFTIR spectra were recorded at RT between 4000 and 650 cm-1 with a resolution of 4 cm-
1, using an OPUS 5.5 software.  
 
 
4.1.2 Carboxylation and characterization of BioPiva™ softwood kraft lignin (III, IV) 
 
Using a similar process as described above, 100 mg of BioPiva™ softwood kraft lignin was 
reacted with different mass ratios of succinic anhydride (as detailed in publication III), in the 
presence of 20 mg of DMAP as catalyst, in a final volume of 40 mL of THF at RT for 48 h.292 
The same procedure for purification and freeze-drying of the carboxylated polymers was 
followed as described in the Section 4.2.1. All the carboxylated lignin polymers were posteriorly 
characterized with a ATRFTIR. Additionally, aliphatic hydroxyl, phenolic hydroxyl, and 
carboxyl groups of original softwood kraft lignin and carboxylated lignin polymers were 
analyzed by phosphorus-31 nuclear magnetic resonance (31P NMR) spectroscopy (III), as 
described earlier, except that now the sample weight was 25 mg and 15 sec relaxation time 
was used in the inverse-gated pulse sequence.103  
After optimization of the carboxylation conditions, the carboxylated lignin polymer (4:1) 
was selected to prepare the LNPs in the subsequent studies (III, IV). 
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4.2 Preparation and characterization of lignin nanoparticles (LNPs) (I-IV) 
 
4.2.1 Preparation of LNPs (I-IV) 
 
All the LNPs were prepared using the solvent exchange method, as described previously.76 
The LNPs were formed during the dialysis process (Spectra/Por® 1 Standard RC Dry Dialysis 
Tubing, 12–14 kDa, Spectrum Labs, USA), in which the lignin molecules self-assembled into 
colloidal spheres as the THF was gradually replaced by deionized water. 
Pure LNPs (pLNPs, I) were prepared after dissolving 1 mg of original LignoBoost™ 
softwood kraft lignin in 1 mL of THF, and dialyzed against water periodically replaced under 
slow stirring in a fume hood for 24 h. 
The synthesis of iron(III)-complexed LNPs (Fe-LNPs, I) was performed, as described 
elsewhere.78 Briefly, a condensation reaction was performed by adding a solution Fe(OiPr)3 in 
THF into a solution of lignin in THF. A hydrolysis reaction was done after the addition of an 
equal volume of 1 wt-% water in THF to a solution of Fe:lignin in THF. Finally, the particles 
were solvent exchanged in a dialysis tube against deionized water that was periodically 
replaced during 24 h to minimize the residual solvents. 
A mixture containing 50:50 w/w of lignin solution and oleic acid-coated Fe3O4 NPs in THF 
was prepared for the synthesis of Fe3O4-infused LNPs (Fe3O4-LNPs, I), and placed into a 
dialysis bag for solvent exchange against deionized water for 24 h.  
The carboxylated LNPs were prepared after dissolving 1 mg of carboxylated 
LignoBoost™ softwood kraft lignin (II) or carboxylated BioPiva™ softwood kraft lignin (III, IV) 
with 1 mL of THF, and the mixture was dialyzed against deionized water during 24 h. 
 
 
4.2.2 Surface functionalization of carboxylated LNPs (II–IV) 
 
4.2.2.1 Preparation of PEG-poly(histidine) and CPP-functionalized LNPs (II)  
 
The conjugation reaction between the –COOH groups of carboxylated lignin and –NH2 groups 
of NH2-PEG-Poly(histidine) (PHIS) and CPP was performed in 10 mM of 2-(N-
morpholino)ethanesulfonic acid (MES) buffer (pH 5.5), using 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide and N-hydroxysuccinimide (EDC/NHS) coupling 
chemistry.293,294 After optimization of the conjugation conditions, to obtain LNPs conjugated 
with a 9 amino acid cell penetrating peptide (CPP), 1 mg of LNPs were activated using 400 μL 
of 10 mM of MES buffer (pH 5.5), with 2.5 μL of EDC (20 mM) and 2.3 mg of NHS (50 mM), 
and stirred at 500 rpm for 1 h at RT. After removing the excess of EDC/NHS, the LNPs were 
resuspended with 1 mL 1× Hanks’ balanced salt solution with 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HBSS–HEPES, pH 7.4), containing 0.2 mg of CPP (mass ratio 
CPP:LNPs of 1:5), and the mixture was reacted for 4 h under stirring, at RT. Finally, the CPP-
functionalized LNPs (LNPs-CPP) were centrifuged and washed twice with HBSS–HEPES (pH 
7.4). 
In order to obtain the NH2-PEG-PHIS-modified LNPs (LNPs-PEG-PHIS), 1 mg of LNPs 
was activated for 1 h, using the same conditions, as described above. After removing the 
excess of EDC/NHS, the LNPs were resuspended with 1 mL of 10 mM of MES buffer (pH 5.5), 
containing 0.1 mg of NH2-PEG-PHIS (mass ratio 1:10 of copolymer:LNPs). The mixture was 
stirred at RT for 4 h, and then washed twice with HBSS–HEPES (pH 7.4) to purify the 
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functionalized LNPs. Afterwards, the same protocol used to prepare the LNPs-CPP was 
employed to react the LNPs-PEG-PHIS with the CPP in order to obtain LNPs-PEG-PHIS-CPP. 
 
4.2.2.2 Preparation of iRGD and DSS-modified LNPs (III) 
 
The conjugation reaction between the –COOH groups of LNPs and –NH2 groups of 
dentin phosphophoryn-derived peptide (DSS) and iRGD peptide was also performed using 
EDC/NHS coupling chemistry. The molar amount of peptides used for the reaction was chosen 
taking into consideration the molecular weight of the peptides (see the in original publication), 
and after optimization of the conjugation conditions. The –COOH groups on the LNPs were 
activated by reacting 1 mg of LNPs in 400 µL of 100 mM of MES buffer (pH 5.5), containing 5 
µL of EDC (40 mM) and 4.6 mg of NHS (100 mM), and the mixture was stirred for 1 h at RT in 
the dark. After removing the excess of EDC/NHS, the LNPs were resuspended with 500 µL of 
PBS (pH 7.4), containing 250 µM of the DSS and iRGD and reacted during for 4 h, to prepare 
LNPs-DSS and LNPs-iRGD, respectively. Afterwards, the peptide-functionalized LNPs were 
centrifuged, and washed twice with MilliQ-water.  
 
4.2.2.3 Preparation of mUNO-modified LNPs (IV) 
 
Using the same coupling chemistry described above, 3 mg of LNPs dispersed in 1.2 mL of 10 
mM of MES buffer (pH 5.5), containing 4.5 µL of EDC (12.8 mM) and 1.2 mg of NHS (8.7 mM) 
were reacted for 1 h, and then 15 mg of maleimide-PEG-amine (Mal-PEG-NH2, 2K) in 1.5 mL 
of 10 mM of MES buffer (pH 7) was reacting with the activated LNPs, during 3 h, in order to 
obtain the LNPs-PEG-Mal. Afterwards, the maleimide group on the LNPs-PEG-Mal was used 
to react with the free cysteine groups on 5(6)-carboxyfluorescein (FAM)-Ahx-Cys-NH2 (FAM) 
and FAM-Ahx-CSPGAK-COOH (mUNO) in MilliQ-water for 2 h at RT, rendering LNPs-P-FAM 
and LNPs-P-F-mUNO, respectively. 
 
 
4.2.3 Characterization of LNPs (I–IV) 
 
All the LNPs were characterized for their average particle size (Z-average), polydispersity 
index (PDI) and average zeta (ζ)-potential (surface charge) by dynamic light scattering (DLS) 
and electrophoretic light scattering (ELS), respectively, using a Malvern Zetasizer Nano ZS 
instrument (Malvern Instruments Ltd, UK). In addition, the LNPs were visualized by 
transmission electron microscopy (TEM), using a Jeol JEM-1400 (Jeol Ltd., Tokyo, Japan), 
with an acceleration voltage of 80 kV, in order to characterize their morphology and confirm 
their size distribution.  
To study the magnetic properties of Fe3O4-LNPs (I), the NP suspension was placed in a 
6-well plate, and the photos were taken while the particles were guided and accumulated 
around the magnetic field. Additionally, the hysteresis loop of oleic acid-coated Fe3O4 NPs and 
Fe3O4-LNPs was measured using a vibrating sample magnetometer (MicroMag 3900 VSM; 
Lake Shore Cryotronics, Inc.). The obtained magnetic moment (A m2) versus the applied 
magnetic field (T) was normalized with the amount of Fe3O4 in the sample, and corrected for 
dia/paramagnetic component in order to determine the magnetization value (A m2 kg-1). 
After drying the samples overnight, the functional groups present on the LNP surface of 
the bare and functionalized LNPs (II, III) were evaluated by ATRFTIR.  
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The dissolution experiments of the LNPs were done to evaluate the long-term stability of 
the LNPs prepared with the different carboxylated lignin polymers at physiological conditions 
(III). For that, 50, 200 and 500 µg/mL of LNPs were incubated in Dulbecco’s phosphate buffer 
saline (PBS, pH 7.4), at 37 °C. Then, 100 µL of LNP suspension were withdrawn at determined 
time points (4, 6, 24, 48 and 72 h), and centrifuged at 16100 g for 5 min. Finally, the absorbance 
of the supernatant at λ = 380 nm was measured by UV-Vis spectroscopy, using a Varioskan 
Flash plate reader (Thermo Fisher Scientific Inc., USA), and the dissolution of the LNPs was 
calculated taking into account the absorbance of the dissolved LNPs in EtOH, which 
corresponded to the maximum absorbance that the supernatant would have if the LNPs were 
totally dissolved at physiological conditions. 
 
 
4.2.4 Human plasma stability of LNPs (I, II) 
 
Plasma proteins can interact with the LNPs and affect their fate upon administration. In order 
to evaluate the interaction of the LNPs with the plasma components, the size and ζ-potential 
changes of the LNPs were determined after incubation of the LNP suspensions (200–300 
μg/mL) with 100% human plasma (I, II) at 37 °C during 90–120 min. All the experiments were 
performed in triplicates. 
 
 
4.2.5 Drug loading (I–IV) 
 
In order to assess the ability of pLNPs to load cytotoxic compounds with different solubility 
properties in aqueous media, three different compounds were used as models in the first study 
(I): poorly water-soluble drug (sorafenib, SFN) and cytotoxic agent (1-methyl-8-(propan-2-yl)-
4-(trifluoromethyl)-3H-benzo[cd]azulen-3-one, benzazulene, BZL), and a water-soluble drug 
(capecitabine, CAP). For that, 2 mg of original LignoBoost™ softwood kraft lignin was 
dissolved with 1 mL of THF containing 200 μg of drug (mass ratio 1:10 of drug:lignin), and then 
dialyzed against MilliQ-water during 24 h.  
Based on the results obtained in this first study, BZL was selected as the model drug for 
the following two studies (II, III). Here, the carboxylated LignoBoost™ softwood kraft lignin (II) 
or carboxylated BioPiva™ softwood kraft lignin (III) was dissolved in a THF solution, containing 
the BZL, in a mass ratio BZL:lignin of 1:5 (II) or 1:3 (III). For the publication IV, resiquimod 
(R848) was loaded into LNPs after mixing carboxylated BioPiva™ softwood kraft lignin and 
R848 in THF, in a mass ratio of 1:10 of R848:lignin. All these solutions were placed inside the 
dialysis membrane, and the drug-loaded LNPs were formed during the dialysis process against 
deionized water (periodically replaced) under slow stirring in a fume hood for 24 h in order to 
remove THF and free compound.  
The conjugation reactions of drug-loaded LNPs with the different polymers/targeting 
ligands were performed according to the procedure described in the Section 4.2.2. for the 
empty LNPs. The average drug loading degree (LD) into the LNPs was determined by 
immersing the drug-loaded LNPs in EtOH under vigorous stirring. Afterwards, the solution was 
centrifuged at 16100 g for 5 min, and the supernatant was collected in order to determine the 
drug concentration detected by UV with a high-performance liquid chromatography (HPLC; 
Agilent 1100 series, Agilent Technologies, USA). The experimental conditions used for 
quantification of the drug loaded into the LNPs are detailed in the original manuscripts. 
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4.2.6 In vitro drug release studies (I–III) 
 
BZL and SFN (I) were used to evaluate the in vitro release profiles of free drug and drug-
loaded pLNPs in two different buffers: HBSS–MES (pH 5.5) and HBSS–HEPES (pH 7.4). For 
that, 100 μg of pure drug and 200 μg of drug-loaded pLNPs were immersed in 200 mL and 25 
mL of release media, respectively. As for the second study (II), the in vitro release profiles of 
free BZL and BZL-loaded LNPs was evaluated in HBSS–MES (pH 5.5) and HBSS–HEPES 
(pH 7.4), supplemented with 2% (v/v) Tween-80, and 70 μg of free BZL and 250 μg of BZL-
loaded LNPs were immersed in 60 mL and 20 mL of release media, respectively. In publication 
III, the release profiles of free BZL and BZL-loaded NPs were studied in HBSS–MES (pH 5.5) 
and HBSS–HEPES (pH 7.4), supplemented with 10% (v/v) fetal bovine serum (FBS) after 4h, 
where 30 μg of free BZL and 100 μg of BZL-loaded LNPs were immersed in 10 mL of release 
media. In all the release experiments, the samples were stirred at 150 rpm at 37 °C. At 
scheduled time intervals (up to 24 h), 200 μL of the release media were withdrawn and the 
same volume of fresh preheated release medium was added, keeping the releasing volume 
constant. After spinning down the samples at 16100 g for 5 min, the supernatants were 
collected, and analyzed in HPLC to determine the amount of drug released by measuring the 
drug concentration, using the same HPLC methods as in the determination of the drug loading 
degree.  
In addition, the morphology of the drug-pLNPs during the release was evaluated and 
compared to the drug-loaded pLNPs before the release (I). For that, 200 μL of release medium 
were collected after 4 and 24 h incubation of 1 mg of drug-pLNPs in 1 mL of HBSS–MES (pH 
5.5) and HBSS–HEPES (pH 7.4), stirred at 150 rpm at 37 °C. The samples were placed on a 
carbon-coated copper grid, and air-dried before analysis and visualization using TEM, and the 
average size, PDI and ζ-potential values of the same samples were also characterized by DLS. 
 
 
4.3 In vitro cell-based studies (I–IV) 
 
4.3.1 Cell lines and cell culturing (I–IV) 
 
Human umbilical vein (EA.hy926), human mammary carcinoma (MDA-MB-231 and MCF-7), 
mouse mammary carcinoma (4T1), human lung carcinoma (A549), human prostate cancer 
(PC3-MM2), and human colorectal adenocarcinoma (Caco-2) cell lines were all obtained from 
American Type Culture Collection (ATCC, USA). The EA.hy926, MCF-7, PC3-MM2, A549 and 
Caco-2 cells were grown in Dulbecco's Modified Eagle Medium (DMEM), and the MDA-MB-
231 and 4T1 cells were cultured in Roswell Park Memorial Institute (RPMI), supplemented with 
10% inactivated fetal bovine serum (HIFBS), 1% of non-essential amino acid (NEAA), 1% of 
L-glutamine (200 mM) and 1% of penicillin (100 IU/mL)-streptomycin (100 mg/mL) in 75 cm2 
flasks. EA.hy926 medium was also supplemented with 1% of sodium pyruvate (100 mM). All 
the cells were kept in an incubator (BB 16 gas incubator, Heraeus Instruments GmbH) at 37 °C, 
5% CO2 and 95% relative humidity. The cell culturing medium was changed every 2–3 days, 
and the subculturing was performed when the cells reached 80% of confluence, until the 
moment of the experiments. For this, the cells were harvested with 0.25% (v/v) trypsin-PBS-
ethylenediamine tetraacetic acid (EDTA) solution. 
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4.3.2 Isolation of murine bone marrow derived macrophages and differentiation into 
macrophages (IV) 
 
Both femur and tibia bones were isolated from female 6-8 week old BALB/c mice, and the 
bones were cut and flushed with cold PBS to a Petri dish, assisted with a 21G needle. 
Subsequently, the cell suspension was centrifuged at 500 g for 5 min, suspended with 1 mL of 
Ammonium-Chloride-Potassium (ACK) lysing buffer for 2 min to remove the red blood cells, 
and then 9 mL of PBS were added before centrifugation (500 g for 5 min).295 The bone marrow 
derived macrophages (BMDMs) were then redispersed with RPMI (supplemented with 10% of 
HIFBS, 1% of L-glutamine and 1% of penicillin-streptomycin), and 300000 cells/mL were 
seeded in Petri dishes in 10 mL of RPMI, containing 20 ng/mL of macrophage colony-
stimulating factor (M-CSF). After 3 days, 5 mL of cell culturing medium were exchanged by 5 
mL of fresh RPMI, supplemented with 20 ng/mL of M-CSF. Resting macrophages (so-called 
M0 macrophages) were obtained at day 6, and seeded in 48-well plates at a density of 250000 
cells per well in 0.5 mL of RPMI supplemented either with 20 ng/mL of IL-4 to differentiate into 
M2-like macrophages, or 10 ng/mL of IFN-γ and 100 ng/mL LPS to obtain M1 macrophages. 
They were incubated at 37 °C for 48 h before the flow cytometry analysis to evaluate the 
expression of the cell surface markers, as detailed in the experimental section of publication 
IV. 
 
 
4.3.3 Preparation of three-dimensional cell culturing model (III) 
 
The three-dimensional (3D) spheroids were prepared using the 3D bioprinting method (III). 
Initially, 1.5 mL of cells (PC3-MM2, MDA-MB-231 and A549) were seeded in 6-well plates at a 
density of 400000 cells per well, and allowed to attach overnight. Then, 50 µL of 
NanoShuttle™-PL were added to the cells for their magnetization, and incubated for 8–10 h. 
Afterwards, the cells were washed twice with PBS buffer (pH 7.4) and plated in ultra-low 
attachment 96-well plates at a density of 5000–7000 cells per well, which was then placed over 
a 96-well spheroid magnetic drive. The cells within the solution aggregated in the well plate 
upon the magnetic field, and the spheroids were cultured for 2 days. 
 
 
4.3.4 Cytocompatibility studies (I-IV) 
 
For the two-dimensional (2D) cell culturing model, 15000–30000 cells per well were seeded in 
96-well plates, and allowed to attach overnight. Afterwards, 100 µL of LNPs’ suspensions (I-
IV) and free R848 (IV) in HBSS–HEPES buffer (I) or cell media (II-IV) at different 
concentrations (25–500 µg/mL) were added to each well and the plates were incubated at 37 
C for 24 h. Incubations with HBSS–HEPES buffer (I) or cell media (II-IV) and 1% (v/v) Triton 
X-100 were used as a positive and negative controls, respectively. After equilibrating the plates 
at RT, and washing the wells with 100 µL of HBSS–HEPES buffer, 50 µL of CellTiter-Glo® 
were added to 50 µL of HBSS–HEPES (pH 7.4) in each well. Finally, after stabilizing the plates 
the luminescence was measured using a Varioskan plate reader. The number of viable cells 
in culture was quantified based on the amount of ATP produced by metabolically active 
cells.175,239  
For the 3D cell culturing model (III), after gently transferring the cell spheroids to 96-well 
plates, 50 µL of LNPs suspensions were mixed with 50 μL of NanoLuc® luciferase and MT Cell 
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Viability Substrate in complete cell culture medium, so that the final concentration of NPs was 
ranging from 10 to 100 µg/mL, followed by the incubation at 37 °C, up to 48 h. The RealTime-
Glo™ MT Cell Viability Assay is a nonlytic, homogeneous and bioluminescent assay that 
allows to quantify the luminescence in order to determine the cell viability, using a Varioskan 
plate reader. The number of viable cells was assessed by measuring the reducing potential of 
cells, and thus metabolism.296  
 
 
4.3.5 Detection of reactive oxygen species (I, IV) 
 
The fluorescent 2’,7’-dichlorofluorescein (DCF) probe was used to measure the generation of 
hydrogen peroxide (H2O2), which results from the oxidation of a non-fluorescent compound 
2’,7’-dichlorodihydrofluorescein diacetate (DCFH2-DA) by the intracellular reactive oxygen 
species (ROS). Briefly, 15000–30000 cells per well (MDA-MB-231, MCF-7, PC3-MM2, Caco-
2 and EA.hy926 cells, for publication I; and M2-like macrophages, for publication IV, were 
seeded in 96-well plates, and incubated overnight at 37 °C. Afterwards, 100 μL of LNP 
suspensions (25 to 250 μg/mL) in HBSS–HEPES buffer (I) or cell media (IV) were incubated 
with the cells, for 24 h (I) or 30 min (followed by 48 h incubation with cell medium,  IV) at 37 °C. 
After that, 100 μL of DCFH2-DA (10 μM) in HBSS–HEPES buffer was incubated with the cells 
for 1h, at 37 °C. Cells treated with 0.25% of H2O2 (I) or cell media (IV) were used as controls. 
Afterwards, the fluorescence of DCF (λex = 498 nm; λem = 522 nm) was measured with 
Varioskan plate reader. 
 
 
4.3.6 Hemotoxicity (I) 
 
Red blood cells (RBCs) were isolated from human blood of anonymous donors at the Finnish 
Red Cross Blood Service. For the isolation, the blood sample was diluted with of PBS (pH 7.4) 
(50:50 v/v) and this solution was further layered in Ficoll-Paque PLUS. The mixture was 
centrifuged (1500 g for 40 min) to split up the RBCs from the serum. After extensive washing, 
the RBCs were diluted with PBS (pH 7.4) to obtain a 5% RBCs suspension. Afterwards, 60 μL 
of this suspension was incubated with 240 μL of LNPs’ suspensions (25 and 250 µg/mL) in 
PBS (pH 7.4), up to 12 h at 37 °C. In addition, PBS (pH 7.4) and MilliQ-water were used as 
negative and positive controls, respectively. At defined time points (1, 4, 6 and 12 h), 100 μL 
of the RBC-LNP suspensions were centrifuged (3 min, 16100 g), and the absorbance intensity 
of hemoglobin at 577 nm in the supernatants was measured, using Varioskan plate reader. 
 
 
4.3.7 Antiproliferative experiments (I-III) 
 
The in vitro antiproliferative effect of the pure BZL and BZL-loaded LNPs was assessed using 
the same protocol and the ATP-based cell viability assay described in the Section 4.3.4, for 
both 2D cell (I-III) and 3D (III) cell culturing models. Different concentrations of BZL-loaded 
LNPs (5–250 μg/mL) in HBSS–HEPES buffer (I) or cell media (II, III) were incubated with the 
different cell lines. Additionally, similar concentrations of pure BZL (1.6–68.2 μM) in HBSS–
HEPES buffer (I), or pure BZL previously dissolved with 1–3% of EtOH in cell media (II, III), 
were added to each well. A specific control for pure BZL was also added with the same amount 
of ethanol used in the BZL-loaded LNP dilutions.  
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4.3.8 Cellular association and internalization studies (III) 
 
For the cell-LNP interaction studies (III), the LNPs were loaded with a highly stable fluorescent 
dye 4-[4-(dihexadecylamino)styryl]-N-methylpyridinium iodide (DiA), in a mass ratio of 1:100 
(DiA:LNPs), and the conjugation reactions with the peptides were done as described for the 
empty LNPs (see Section 4.2.2.2). Afterwards, the interactions between the cells and DiA-
loaded LNPs, LNPs-iRGD and LNPs-DSS were qualitatively and quantitatively evaluated by 
confocal microscopy and flow cytometry, respectively.  
For the 2D cell culturing model, 50000 cells per well were seeded in Lab-Tek 8-chamber 
slides for confocal microscopy, and allowed to attach overnight. After removing the medium, 
100 µg/mL of LNP suspensions in PBS (pH 7.4) were added to the cells and incubated for 3 h 
at 37 °C. The cells were washed, and the plasma membranes were stained by adding CellMask 
Red (5 µg/mL) for 3 min at 37 °C. After washing, the cells were fixed using 4% 
paraformaldehyde (PFA) for 10 min at RT, and the nuclei were stained by adding 4’,6-
diamidino-2-phenylindole (DAPI, 2.8 µg/mL) for 5 min at 37 °C. The localization of NPs was 
observed with a Leica SP5 inverted confocal microscope (Leica Microsystems), using a 
63×/1.2-0.6 oil immersion objective.  
For flow cytometry analysis, 100000 cells per well were seeded in 24-well plates and 
allowed to attach during overnight incubation. Afterwards, 100 µg/mL of LNP suspensions were 
added to the cells for 3 h at 37 °C. After removing the non-adherent LNPs, the cells were 
harvested with Gibco™ Versene Solution for 5 min (0.48 mM), incubated with trypan blue 
(0.005% v/v) during 4 min, and washed with PBS (pH 7.4) before analysis. Flow cytometry was 
performed with a LSR II flow cytometer (BD Biosciences, USA), and a FACS Diva software, 
and the data was analyzed using FlowJo V10 software after collecting 20000 events.  
Regarding the 3D cell culturing model, the 3D tumor spheroids (prepared as described in 
the Section 4.3.3) were incubated with 100 µg/mL of LNP suspension in PBS (pH 7.4), at 37 °C 
for 3 h. For confocal microscopy, the spheroids were further fixed with 4% of PFA (24 h at 
37 °C), and the nuclei were stained with DAPI (2.8 µg/mL, for 24 h at 37 °C). Finally, the cell 
spheroids were transferred to a Lab-Tek 8-chamber to observe the localization of NPs with a 
Leica SP5 inverted confocal microscope, using a 20× objective. As for flow cytometry analysis, 
the spheroids were harvested with trypsin-PBS-EDTA during 5 min, after incubation with the 
LNP suspensions. Then, the cells were incubated with trypan blue (0.005% v/v, 4 min) and 
washed with PBSEDTA (pH 7.4) before flow cytometry analysis, using a LSR II flow cytometer 
(BD Biosciences, USA), and FlowJo V10 software to analyze the data after collecting 5000 
events.  
 
 
4.3.9 Immunostainings and cellular association studies (IV) 
 
For flow cytometry, M0 macrophages were seeded in 48-well plates at density of 250000 cells 
per well (500 μL of RPMI supplemented with 20 ng/mL of IL-4), for 48 h at 37 °C, to obtain M2-
like macrophages. Then, LNPs-P-FAM and LNPs-P-F-mUNO (200 μg/mL) were added to each 
well and incubated at 37 °C for 10, 30 and 60 min in complete medium. Afterwards, the 
macrophages were detached using PBS–EDTA (5 mM), during 15 min on ice. The cells were 
centrifuged at 500 g during 5 min, and resuspended in PBS–EDTA for flow cytometry analysis 
(LSR II flow cytometer, BD Biosciences, USA), and the data was analyzed using FlowJo V10 
software after collecting at least 10000 events. 
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As for confocal microscopy, the M0 macrophages were seeded in Lab-Tek 8-chamber 
slides, at density of 75000 cells per well (in 200 μL of RPMI supplemented with 20 ng/mL of 
IL-4), during 48 h, at 37 °C. Next, 200 μg/mL of LNPs-P-FAM and LNPs-P-F-mUNO in 
complete cell culturing medium were added to the M2-like macrophages for 10, 30 and 60 min, 
at 37 °C. Afterwards, the cells were fixed with 4% of PFA (10 min at RT), permeabilized with 
0.2% (v/v) Triton-X in PBS (10 min at RT), and incubated with 5% of blocking buffer (5% Bovine 
serum albumin (BSA) + 5% FBS + 5% Donkey serum in PBS + 0.05% (v/v) Tween-20 (PBS-
T)), for 1 h at RT, in order to avoid unspecific binding of the antibodies. Next, rat anti-mouse 
CD206 and rabbit anti-mouse FAM in 1% of blocking buffer (1% BSA + 1% FBS + 1% Donkey 
serum in PBS-T) were incubated with the cells for 1 h at RT, followed by the incubation with 
the secondary antibodies anti-rat Alexa Fluor 647 and anti-rabbit Alexa Fluor 488 in 1% of 
blocking buffer (35 min at RT). Finally, the nuclei were stained with DAPI (5 min, at RT). The 
samples were observed with a Leica SP5 inverted confocal microscope, using a 63×/1.2–0.6 
oil immersion objective. The colocalization of the LNP FAM signal with CD206+ M2-like 
macrophages (Pearson’s coefficient) was quantified using ImageJ software. 
 
 
4.3.10 Repolarization study (IV) 
 
The expression of specific cell surface markers on macrophages was evaluated after in vitro 
repolarization of M2-like macrophages. For that, after the differentiation of M0 macrophages 
into M2-like macrophages, 200 µg/mL of R848-loaded LNPs and a similar concentration of free 
R848 (1 µg/mL) in complete media were added to each well, for 30 min at 37 °C, and further 
replaced by fresh complete medium for 48 h at 37 °C. After detaching the macrophages, the 
samples were incubated with TruStain FcX™ anti-mouse CD16/32 antibody (BioLegend, USA) 
in cold PBS during 10 min at 4 °C, before staining with anti-mouse Alexa Fluor 488–CD86 and 
APC–CD206 (BioLegend, USA) in cold PBS for 20 min at 4 ºC. Finally, the samples were 
analyzed by flow cytometry (LSR II flow cytometer, BD Biosciences, USA), and the data was 
analyzed by FlowJo V10 software after collecting at least 10000 events.  
 
 
4.4 In vivo studies (IV) 
 
The nanoplatform developed in the publication IV was assessed in vivo, using a murine breast 
adenocarcinoma model (4T1 tumor-bearing mice), for combination with chemotherapy. 
 
 
4.4.1 Experimental model and ethical permit (IV) 
 
The 4T1 tumors were inoculated according to protocols approved by the Estonian Ministry of 
Agriculture, Committee of Animal Experimentation (permit #48). Here, female 8-12 week old 
Balb/c mice (in-house bred) were inoculated orthotopically by injecting 1 million 4T1 cells (in 
50 µL of PBS) in the 5th mammary fat pad. The tumor dimensions were measured using a 
digital caliper, and the tumor volumes were calculated using the formula [(W2 × L)/2], in which 
W is the tumor width and L is the tumor length. 
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4.4.2 Homing study and ex vivo biodistribution (IV) 
 
The tumor homing of R848-loaded LNPs-P-FAM and LNPs-P-F-mUNO was evaluated 6 days 
after tumor inoculation, when the tumors reached a volume of ca. 50 mm3. Then, 250 µg of 
LNPs were dispersed in 200 µL of 5.4% glucose, and administered intraperitoneally. After 3 h, 
mice were sacrificed by i.p. administration of 500 µL of 2.5% Avertin and cervical dislocation, 
and the tumors and organs were excised, washed with PBS and fixed with 4% of PFA (4 °C, 
overnight). The tissues were further placed in 15% of sucrose (in PBS, overnight), and later in 
30% of sucrose. Afterwards, the tissue blocks were frozen, cut into 20 µm-thick sections (Leica 
cryotome), and placed onto glass slides before storing at 20 °C.  
For immunostaining purposes, the tissue sections were incubated with rat anti-mouse 
CD206 and rabbit anti-FAM as the primary antibodies, and then with anti-rat Alexa Fluor 546 
and anti-rabbit Alexa Fluor 647 as the secondary antibodies. Finally, the nuclei were stained 
with DAPI, and the sections were mounted and sealed, before imaging with a Zeiss LSM-710 
confocal microscope (Germany). The total FAM signal and colocalization (Pearson’s 
coefficient) of both FAM and CD206 channels were estimated using ImageJ software. 
 
 
4.4.3 Therapeutic studies and ex vivo immunological profile of tumor cells (IV) 
 
On day 6 post-inoculation (p.i.), mice were randomly distributed into 5 treatment groups (n = 
6) according to their tumor volume average (46–48 mm3). Then, mice were initially treated 
three times with Vinblastine alone (1 mg/kg, in 500 µL of PBS, i.p.) or vinblastine combined 
with free R848 or R848@LNPs (0.125 mg/kg, in 200 µL of 5.4% glucose, i.p.), followed by two 
isolated administrations of the R848 (free form or nanoformulated). Detailed description of the 
treatment schedule is provided in the original publication. The mice weights and tumor volumes 
were measured every other day. On day 18 of p.i., all mice were sacrificed, and their tumors 
were weighed.  
Tumor tissues from each treatment group (n = 3) were further used for evaluating the 
immunological profile of the cells. For that, single cell suspensions were obtained after gentle 
disruption of the tumor tissues using cell strainers (70 μm mesh) with a syringe plunger. 
Samples were then cryopreserved at −80 °C (in FBS containing 5% of DMSO) until the day of 
analysis. After thawing, the samples were incubated with ACK lysis buffer, and the cells were 
incubated with TruStain FcX™ anti-mouse CD16/32 antibody (10 min, at RT), followed by 
staining with antibody combinations (20 min, at 4 °C). After washing twice with PBS, the 
samples were analyzed by flow cytometry (BD Accuri 6 plus, BD Biosciences, USA), and the 
data analysis was performed using FlowJo V10 software, after collecting 500000 events. The 
antibodies to stain specific markers on the cell surface were the following: macrophages (PE-
F4/80, APC-CD206 and Alexa Fluor 488-CD86), T cells (Alexa Fluor 488-CD3 and APC-CD8), 
and DCs (FITC-CD11c and APC-CD86). 
 
 
4.5 Statistical analysis (I-IV) 
 
The measured values are expressed by mean ± standard deviation (s.d.). Statistical analysis 
was performed using the GraphPad Prism (GraphPad software Inc., CA, USA), and set at the 
probabilities of *p < 0.05, **p < 0.01 and ***p < 0.001. Detailed description of the statistical 
methods used to analyze the data can be found in the experimental section of each publication. 
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5 Results and Discussion 
 
Lignin has recently emerged as a novel starting material for different biomedical applications. 
In this thesis, the potential use of this underexplored material was evaluated for drug delivery 
purposes. In particular, different LNP platforms were evaluated in terms of their biocompatibility 
towards various cell lines, the ability to load different therapeutic compounds, and to modify 
their surface with different ligands. Lastly, the potential ability of LNPs to deliver an 
immunomodulatory compound for synergistic effect with chemotherapy was assessed also in 
vivo. 
 
 
5.1 In vitro evaluation of LNPs for drug delivery and enhanced antiproliferative 
effect in cancer cells (I) 
 
The physicochemical properties of NPs play an important role in the biodistribution, 
internalization, pharmacokinetics and safety of the chemotherapeutics. The NP’s biological 
fate can be influenced by structural and physical parameters, such as size, shape, surface 
charge and chemistry.9,297 The main aim of this study was to fabricate and characterize LNPs 
in terms of their physicochemical properties, biocompatibility, stability in biorelevant media, 
and ability to load and release different cytotoxic compounds.  
 
 
5.1.1 Characterization of LNPs 
 
Here, three different lignin-based NPs were prepared by solvent exchange, intended to be 
used as vehicles to deliver anticancer agents: pure LNPs (pLNPs); iron(III)-complexed LNPs 
(Fe-LNPs), and oleic acid-coated Fe3O4-loaded lignin NPs (Fe3O4-LNPs), as shown in Figure 
7A. These nanosystems were firstly characterized by DLS (Table 5) and TEM (Figure 7B-D), 
in order to assess their average size diameter and distribution, surface charge, and also their 
morphology. 
 
Table 5. Physicochemical characterization of the fabricated lignin-based NPs. 
Sample Size (nm) PDI ζ-Potential (mV) 
pLNPs 220 ± 10 0.19 ± 0.02 44 ± 4 
Fe-LNPs 160 ± 21 0.09 ± 0.01 43 ± 2 
Fe3O4-LNPs 464 ± 15 0.22 ± 0.06 42 ± 1 
 
With the exception of the Fe3O4-LNPs, both pLNPs and Fe-LNPs showed an average size that 
fulfils the requirements for a passive targeting of NPs to the tumor tissue, in response to the 
large fenestrations and discontinuous endothelium present in the blood vessels in the vicinity 
of the tumor tissue.298 Additionally, the PDI values lower than 0.25 are indicative of a 
moderately uniform size polydispersity of the prepared LNPs. Regarding the surface charge, 
all the LNPs presented ζ-potential values of ca. 43 mV, driven by the negatively charged 
functional groups on the LNP surface (in water) that promote the formation of electrical double 
layers, which then stabilize the NP dispersion through electrostatic repulsion.76 Additionally, 
TEM images revealed symmetric and spherically shaped LNPs (Figure 7B-D), which can be 
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ascribed to the good solubility of the lignin polymer in THF and poor solubility in water that 
allowed a proper interaction between the water and lignin in the course of the solvent exchange 
process. 
 
 
Figure 7. Schematic representation of the three types of LNPs evaluated in this study (A), 
TEM images of (B) pLNPs, (C) Fe-LNPs and (D) Fe3O4-LNPs and magnification of the Fe3O4 
NPs inside the LNPs. Characterization of the magnetic behavior of the Fe3O4-LNPs (E); 
Sequence of images showing the magnetic-guided behavior of Fe3O4-LNPs in suspension: 1, 
Fe3O4-LNPs in suspension; 2 and 3, Fe3O4-LNPs accumulated around the magnetic field after 
placing the magnet under the well; 4 and 5, Fe3O4-LNPs guided by the magnetic field after 
moving the magnet under the well; 6, Fe3O4-LNPs redispersed by gently shaking. (F) 
Hysteresis loop of Fe3O4 NPs and Fe3O4-LNPs. Copyright © 2017 Elsevier B.V. Adapted and 
reprinted with permission from publication (I). 
 
 
The magnetic properties of the Fe3O4-LNPs were also evaluated (Figure 7E and 7F). For an 
efficient loading of the Fe3O4 NPs into LNPs, the Fe3O4 NPs were coated with oleic acid, which 
provided hydrophobicity and also better dispersibility for the magnetic NPs,299 allowing the 
Fe3O4 NPs to be loaded during the solvent exchange process from THF to water. As shown in 
the TEM image (Figure 7D), around 10 nm diameter Fe3O4 NPs can be found loaded inside 
the LNPs, suggesting a successful formation of Fe3O4-LNPs, and the loading degree of Fe3O4 
NPs was ca. 9.9 wt-%. The magnetic behavior of the Fe3O4-LNPs was assessed after 
magnetically guiding the NP suspension (Figure 7E). It was possible to observe that the Fe3O4-
LNPs accumulated and translocated to another place of the well, towards the point where the 
magnetic field applied was higher, and they were easily redispersed by gently shaking.  
Classified as superparamagnetic iron oxide NPs, the Fe3O4 NPs also exhibited a 
superparamagnetic behavior shown by NP sizes of about 10–20 nm. These NPs reached 
saturation magnetization after the application of an external magnetic field. After removing the 
magnetic field, the NPs retained no residual magnetic interaction and they could be easily 
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redispersed.300 In this way, the hysteresis loop given by the magnetization versus magnetic 
field curves of Fe3O4 NPs and Fe3O4-LNPs allowed to evaluate the magnetic properties 
(Figure 7F). The results indicated that the superparamagnetic properties of the Fe3O4-LNPs 
were retained after loading of the Fe3O4 NPs into LNPs, despite of the decrease on the 
saturation magnetization values after the loading of the Fe3O4 NPs, from 31 to 7 A m2 kg-1. The 
decrease in the saturation magnetization can be ascribed to the larger size of the Fe3O4-LNPs 
compared to the Fe3O4 NPs alone, a phenomenon that has been reported in the literature for 
other magnetic nanosystems.301,302 Therefore, due to the superparamagnetism of the 
developed Fe3O4 NPs, they could be used as a delivery vehicle to a specific target in the body 
upon magnetic field exposure, for example for cancer diagnosis and therapy, and magnetic 
resonance imaging.183,303 
Another aspect to take into consideration is the NP stability at physiological conditions 
and, therefore, the stability of the three types of LNPs were evaluated in PBS (pH 7.4) and in 
human plasma. Upon incubation with the PBS (Figure 8A), the sizes of the LNPs were 
constant over time and they did not form aggregates, indicating that the prepared LNPs 
presented a good colloidal stability. However, the sizes of LNPs were generally increased 
during the first minutes of incubation in human plasma (Figure 8B), indicating a certain degree 
of plasma protein adsorption onto the LNPs. Although the sizes slightly decreased over time, 
owing to the slow detachment of weakly interacting proteins from the hard protein corona layer 
on the LNP surface,304 their final sizes after incubation with plasma were ca. 200 nm higher 
than their initial size. The grafting of hydrophilic polymers (e.g., PEG) on the NP surface could 
minimize the protein corona formation, improving plasma stability and, consequently, increase 
the circulation time in the bloodstream upon in vivo administration.219,305 
 
 
Figure 8. Stability of the LNPs in terms of average size, up to 2 h incubation at 37 °C in (A) 
PBS (pH 7.4), and (B) human plasma. Error bars represent mean ± s.d. (n = 3). Copyright © 
2017 Elsevier B.V. Adapted and reprinted with permission from publication (I). 
 
 
5.1.2 In vitro cytocompatibility studies 
 
Although the three LNPs were prepared with the same starting material, different cellNP 
interactions, biological activities (e.g., ROS production), and NP-associated cytotoxicity could 
be observed in response to the different surface compositions (e.g., presence of iron), 
aggregation behavior, and sizes.304,306–308 Therefore, toxicological effects on the cells after 
exposition to the LNPs were investigated by evaluating the cell viability values in terms of ATP 
production (Figure 9AE) and production of H2O2 (Figure 9FJ), as a function of the 
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concentration of the LNPs. Different cancer cell lines were selected in order to evaluate the 
potential application of these LNPs in the treatment of different types of cancer, such as breast 
(MDA-MB-231, MCF-7), prostate (PC3-MM2) and colorectal (Caco-2) cancers. Additionally, a 
non-tumor EA.hy926 endothelial cell line was also selected, because of the potential 
application of these LNPs for i.v. administration. 
 
 
Figure 9. Cell viability of (A) MDA-MB-231, (B) MCF-7, (C) PC3-MM2, (D) Caco-2 and (E) 
EA.hy926 cell lines after incubation with pLNPs, Fe-LNPs and Fe3O4-LNPs at different 
concentrations for 24 h at 37 °C. The cell viability was determined using the CellTiter-Glo® 
luminescence assay and all data sets were compared to the positive control (HBSS–HEPES, 
pH 7.4). Evaluation of ROS production in (F) MDA-MB-231, (G) MCF-7, (H) PC3-MM2, (I) 
Caco-2 and (J) EA.hy926 cell lines after 24 h incubation at 37 °C with pLNPs, Fe-LNPs and 
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Fe3O4-LNPs at different concentrations. The ROS production was determined with a 
fluorescent DCFH2-DA assay. All data sets were compared with the positive control (H2O2). 
Errors bars represent the mean ± s.d. (n ≥ 3). The level of the significant differences was set 
at probabilities of *p < 0.05, **p < 0.01 and ***p < 0.001. Copyright © 2017 Elsevier B.V. 
Adapted and reprinted with permission from publication (I). 
 
 
Overall, all the tested concentrations of the three types of LNPs showed very good 
cytocompatibility at concentrations up to at least 100 µg/mL after 24 h of incubation, with more 
than 80% of cell viability values (Figure 9AE). However, the Fe3O4-LNPs at concentration of 
250 µg/mL showed an increased toxicity towards MDA-MB-231, MCF-7, and EA.hy926 cell 
lines, and the Fe-LNPs (250 µg/mL) were also toxic against MDA-MB-231 cells. This higher 
cytotoxicity of the NPs can be correlated with an increased production of H2O2 against the 
same cell lines (Figure 9FJ), after conversion into highly reactive superoxide or hydroxyl 
radicals by Fenton reaction, which is a process catalyzed by Fe2+/Fe3+ ions.308–310  Additionally, 
the presence of iron ions and iron oxide NPs can also affect the homeostasis of ROS inside 
the cells and the intracellular redox reactions, leading to the conversion of ROS into highly 
reactive superoxide or hydroxyl radicals, and consequent oxidative stress.308–310 This effect 
can then lead to DNA damage, unregulated cell signaling, cytotoxicity, and finally 
apoptosis.311,312 
In general, no significant cytotoxicity and intracellular ROS production was observed at 
LNP concentrations up to at least 100 µg/mL, after 24 h of incubation with the different cell 
lines. 
 
 
5.1.3 Drug loading assessment and release studies 
 
The potential of pLNPs to be used as a vehicle for drug delivery applications was further 
studied using three different drugs and cytotoxic agents with different solubility profiles: poorly 
water-soluble compounds (SFN and BZL), and water-soluble drug (CAP), were used as model 
drugs for loading into pLNPs during the solvent exchange process.  
The loading degrees (LD) of the different drugs were quantified after completely 
releasing the drugs during the incubation of pLNPs with ethanol, which caused the dissolution 
of the lignin polymer (Figure 10B). This slight difference between the LD of BZL (8%) and SFN 
(7%) can be ascribed to the different molecular weight, chemical structures, and solubility 
characteristics of these drugs. As the BZL is more hydrophobic and smaller compared to SFN, 
it can be encapsulated more efficiently into the pLNPs than SFN. For the same reason, the 
SFN@pLNPs also showed a larger size than BZL@pLNPs, and the sizes of both the drug-
loaded pLNPs were slightly higher compared to the empty pLNPs (Figure 10A). Moreover, the 
PDI values were lower than 0.25, and the surface charge of the drug-loaded pLNPs did not 
change significantly, suggesting that the pLNPs were still monodispersed even after the drug 
loading, and the drugs were successfully loaded and were not on the pLNP’s surface. However, 
the solvent exchange method to prepare pLNPs did not allow the encapsulation of hydrophilic 
drugs, such as CAP (Figure 10A and 10B). This suggests the potential of using pLNPs as a 
carrier for poorly water-soluble cytotoxic agents and drugs (e.g., BZL and SFN). 
The drug release profiles of BZL@pLNPs, SFN@pLNPs and free drugs were evaluated 
in two different aqueous buffers to mimic the tumor microenvironment or intracellular 
endosomes (pH 5.5, Figure 10C) and the physiological pH (pH 7.4, Figure 10D). Overall, the 
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drug-loaded pLNPs improved the drug dissolution rates at pH 5.5 and 7.4, because both pure 
BZL and SFN present very low solubilities in aqueous solutions (< 5% release after 24 h). 
However, the amount of SFN released from the pLNPs was slightly decreased after 24 h, which 
could be due to the instability and consequent precipitation of SFN in the aqueous solution. 
Therefore, the pLNPs could protect the hydrophobic drugs inside the nanostructure, while 
substantially improving the dissolution profiles.  
 
 
Figure 10. Characterization of the drug-loaded pLNPs: (A) Size, PDI, and ζ-potential, (B) 
loading degree and solubility kinetics of pure drugs and drug-loaded pLNPs in (C) HBSS–MES 
(pH 5.5) and (D) HBSS–HEPES (pH 7.4) at 150 rpm and 37 °C for 24 h. Results are presented 
as mean ± s.d. (n = 3). TEM pictures taken during the release study: (E and J) drug-loaded 
pLNPs, (F and K) drug-pLNPs after 4 h release at pH 5.5, (G and L) drug-pLNPs after 24 h 
release at pH 5.5, (H and M) drug-pLNPs after 4 h release at pH 7.4, and (I and N) drug-
pLNPs after 24 h release at pH 7.4. Copyright © 2017 Elsevier B.V. Adapted and reprinted 
with permission from publication (I). 
 
 
The morphology and size of the drug-loaded pLNPs before and during the release were 
evaluated with the aim to demonstrate reasoning for the release mechanism of both the drugs 
from the pLNPs (Figure 10E-N). First of all, the drug-loaded pLNPs were also spherically 
shaped as the empty pLNPs, indicating that the morphology did not change after drug loading. 
After incubation at pH 5.5 (Figure 10F, G, K, L), both the drug-loaded pLNPs showed some 
disintegration of the NPs, and possibly the formation of aggregates, as the sizes were 
increased from about 300 to 600 nm after 4 and 24 h of release, respectively. Regarding the 
incubation of drug-loaded pLNPs at pH 7.4 (Figure 10H, I, M, N), a less significant 
disintegration of the NPs was observed, and the size increases were smaller, from 300 to 400 
nm after 4 and 24 h, respectively.  
Overall, these observations suggested that the drug release from the pLNPs can be 
dictated by a diffusion mechanism through the lignin structure. 
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5.2 Functionalization of LNPs for pH-responsive delivery of a cytotoxic agent 
(II) 
 
Different polymers have been employed to efficiently deliver the therapeutic compounds into a 
specific site of action.313 In particular, the advantageous properties of PEG allow the PEGylated 
NPs to prolong their circulation time in the bloodstream, by avoiding opsonization and 
clearance by the MPS.198,219 Additionally, the use of pH-responsive polymers (e.g., PHIS) can 
trigger the drug release in response to the lower pH values of the TME (pH 5.5–6.8).246,247 In 
this study, the original lignin polymer was subjected to a carboxylation reaction in order to 
increase the amount of carboxyl groups available for further conjugation reactions with different 
polymers/ligands. After characterization of the prepared nanosystems, the drug release profile 
of poorly-water soluble BZL-loaded LNPs was evaluated, and their in vitro antiproliferative 
effects in different cell lines studied. 
 
 
5.2.1 Carboxylation and characterization of LNPs 
 
The carboxylation of the lignin polymer was done by reacting the hydroxyl groups of the original 
lignin with succinic anhydride, with DMAP as a nucleophilic catalyst.292 The potential 
mechanism for this reaction starts with the nucleophilic attack of DMAP on a carbonyl group 
of succinic anhydride that leads to the formation of a tetrahedral intermediate. This 
intermediate is more active than the original anhydride towards a further nucleophilic attack, 
and will react with the hydroxyl groups on lignin, originating another intermediate that will 
collapse to obtain the carboxylated lignin upon elimination of the pyridine group.314 In the 
ATRFTIR spectra in Figure 11C of the original lignin polymer and carboxylated LNPs (simply 
referred to as LNPs), shows the success of the carboxylation reaction. In addition to the typical 
bands attributed to the different functional groups on the lignin structure (e.g., aromatic 
structure (1427–1512 cm–1), carbonyl groups (1600 cm–1), and alcohol and phenol –OH (3500–
3100 cm–1)), the LNPs exhibited a stronger absorption band at about 1720 cm–1 compared to 
the original lignin. Apart from the contribution of the stretching vibrations of C=O derived from 
the ketone group positioned at β-location, which also appeared in the original lignin, this 
stronger absorption was mainly due to the stretching vibrations of C=O of the free –COOH 
groups. 
Afterwards, water-dispersed LNPs prepared with the carboxylated lignin were also 
formed by solvent exchange process via dialysis. Therefore, a block copolymer NH2-PEG-
PHIS was attached to the LNP surface to provide the aforementioned PEGylation effect and a 
pH-responsive behavior of PHIS.198,219,315 Additionally, the LNPs were also decorated with a 
CPP (polyarginine R9), a highly positively charged peptide that is known to enhance the 
translocation through the plasma membrane, which is negatively charged.316 Regarding the 
characterization of the prepared LNPs, the average sizes of both CPP or PEG-PHIS-CPP-
functionalized LNPs were slightly increased after the conjugation reaction, compared to the 
bare LNPs, and the PDI values remained below 0.25, suggesting a moderate polydispersity of 
all the prepared LNPs (Figure 11A). As for the surface charge, the ζ-potential values of the 
bare LNPs were negative (ca. 36 mV), due to the presence of free –COOH groups on the 
LNP surface (Figure 11B). However, the surface charge become positive after the surface 
modification of LNPs, because of the –NH2 groups presented by both CPP and PHIS, 
 Results and Discussion  
 
 48  
 
indicating that the functionalization of the LNPs with NH2-PEG-PHIS and CPP was successfully 
accomplished.  
 
 
Figure 11. Characterization of carboxylated LNPs and functionalized carboxylated LNPs by 
(A) measuring their average size and PDI; (B) ζ-potential, and (C) ATRFTIR spectroscopy. 
Error bars represent the mean ± s.d. (n ≥ 3). Copyright © 2017 Future Science Group. Adapted 
and reprinted with permission from publication (II). 
 
 
The ATRFTIR spectra were also recorded to determine the functional groups present on the 
LNP surfaces, and to evaluate the differences between bare LNPs and modified-LNPs (Figure 
11C). All the prepared LNPs presented an adsorption band at around 1720 cm–1, due to the 
C=O stretching vibrations of the unconjugated –COOH groups. However, both the LNPs-CPP 
and LNPs-PEG-PHIS-CPP showed a characteristic band absorbing near 1670 cm–1, ascribed 
to the C=O stretching vibrations of the amide bond (O=C–NH), with minor contributions from 
the out-of-phase C–N stretching vibration, the N–H in-plane bend and the C–C–N 
deformation.317,318 At the same time, the intensity of the band at 1720 cm–1 for the functionalized 
LNPs was decreased compared to the bare LNPs, while a small band at ca. 1640 cm–1 
emerged, which could be due to the free –NH2 groups present on both CPP and PHIS.319 The 
ATRFTIR spectrum of a physical mixture, composed by LNPs and PEG-PHIS mixed together, 
was also determined to compare with the chemically modified LNPs-PEG-PHIS-CPP. Here, 
the absorption bands were slightly different from those observed for the LNPs, but the 
characteristic band corresponding to the amide bond formation (1670 cm–1) was reduced, while 
a stronger band at ca.1640 cm–1 was present due to the free –NH2 groups on the PHIS. 
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Concluding, the ATRFTIR spectra along with the obtained ζ-potential values for the 
LNPs indicated that the conjugation reactions were successfully achieved through an amide 
bond formation. 
 
 
5.2.2 pH-Responsive drug release and delivery into cancer cells 
 
Here, the poorly water-soluble cytotoxic compound (BZL) was selected as a model drug, 
because of its ability to inhibit the Pim kinases, which are frequently overexpressed in some 
solid tumors (e.g., prostate and colon cancers), and are implicated in promoting the cell survival 
and developing resistance against chemo- and radiation-therapies.320–322 
The BZL@LNPs were again prepared by solvent exchange, and further conjugated with 
PEG-PHIS and/or CPP. The LDs of BZL into the LNPs, LNPs-CPP and LNPs-PEG-PHIS-CPP 
were 11, 10 and 9%, respectively, decreasing slightly along the conjugation reactions. 
Afterwards, the release profiles of pure BZL and BZL@LNPs were evaluated in two different 
aqueous buffers, mimicking the tumor microenvironment/acidic endosomal (pH 5.5, Figure 
12A) and the physiological pH values (pH 7.4, Figure 12B).323 The dissolution of the pure BZL 
at pH 5.5 was slightly slower than at pH 7.4, and reached a plateau at around 48% after 24 h 
for both the pH values tested. When loaded into LNPs, the BZL release profile was strongly 
improved, in particular at pH 5.5 (ca. 100% after 24 h). However, a decreased dissolution of 
BZL was observed for all the BZL@LNPs at pH 7.4 after 24 h, when compared to the BZL 
released from the LNPs at pH 5.5, which can be ascribed to the possible precipitation or 
degradation of BZL.  
Generally, the three LNPs, before and after functionalization, showed the following trend 
for the release of BZL in both the pH values: BZL@LNPs > BZL@LNPs-CPP > BZL@LNPs-
PEG-PHIS-CPP. The decoration of the LNP surface with the block copolymer or CPP seemed 
to slightly prevent the release of BZL from the LNPs, acting as a drug release barrier. In 
addition, the ionic interactions between the BZL and the attached ligands could also affect the 
release profile of BZL.324 Moreover, the BZL@LNPs-PEG-PHIS-CPP showed a sustained 
release of BZL compared to the bare BZL@LNPs and CPP-functionalized BZL@LNPs at pH 
5.5. Additionally, the release of BZL from BZL@LNPs-PEG-PHIS-CPP was more efficient at 
pH 5.5 than pH 7.4, showing a pH-responsive behavior that could be correlated with the 
presence of a basic nitrogen atom on the imidazole ring of PHIS, which after protonation leads 
to a change on the conformation of the block copolymer on the LNP surface and, consequently, 
allows the drug release.246,315  
Overall, the BZL@LNPs showed improved dissolution rates along with pH-responsive 
release of the BZL compound, by diffusion through the lignin structure. 
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Figure 12. Release profiles of pure BZL and BZL-loaded carboxylated LNPs in (A) HBSS–
MES (pH 5.5) and (B) HBSS–HEPES (pH 7.4), containing 2% (v/v) Tween-80 at 150 rpm at 
37 °C for 24 h. (C) Representation of the half maximal inhibitory concentration (IC50) values, 
obtained after the antiproliferative studies of MDA-MB-231, PC3-MM2, Caco-2 and EA.hy926 
cell lines treated with pure BZL (blue), previously dissolved with 1% EtOH, BZL@LNPs (green), 
BZL@LNPs-CPP (yellow) and BZL@LNPs-PEG-PHIS-CPP (orange) after 24 h of incubation 
with the different cell lines. Error bars represent the mean ± s.d. (n ≥ 3). Copyright © 2017 
Future Science Group. Adapted and reprinted with permission from publication (II). 
 
 
Finally, the antiproliferative effects of the BZL@LNPs were studied using MDA-MB-231, PC3-
MM2 and Caco-2 cells to represent the breast, prostate and colon cancers, respectively. In 
addition, a non-tumor endothelial cell line (EA.hy926) was also evaluated to compare the 
cytotoxicity effect caused by the BZL released from the LNPs in a physiological environment 
with the TME present in cancer cells. Here, the growth inhibition effect of BZL@LNPs was 
compared with equal molar ratio of pure BZL, previously dissolved with 1% EtOH and diluted 
with cell culture media (Figure 12C). Generally, a similar trend on the growth inhibition effect 
were observed for pure BZL and BZL@LNPs, before and after surface modifications, within 
the same cell lines. Upon incubation with the three cancer cell lines, the LNPs showed a lower 
half maximal inhibitory concentration (IC50) values, thus, were more efficient in decreasing the 
cell viability than the free BZL. Here, the growth inhibition effect of the BZL@CLNPs showed 
the following trend in cancer cell lines: BZL@LNPs-PEG-PHIS-CPP > BZL@LNPs > 
BZL@LNPs-CPP > pure BZL. However, upon incubation with a non-tumor EA.hy926 cells, the 
BZL@LNPs-PEG-PHIS-CPP showed the highest IC50 (45.1 μM), compared with the pure BZL, 
BZL@LNPs and BZL@LNPs-CPP (ca. 31 μM). This indicates that the coating with PEG-PHIS 
slowed down the BZL release from the LNPs-PEG-PHIS-CPP in physiological environment 
and, consequently, caused less toxic effects to the normal cells.   
Taking everything into account, the functionalization of LNPs with PEG-PHIS-CPP was 
found to be an advantageous approach to slow down the drug release, and the BZL@LNPs 
inhibited efficiently the cell growth in all the cancer cell lines tested, due to the enhanced 
solubility of BZL when loaded into the LNPs, without using an organic solvent to pre-solubilize 
the BZL.  
 
 Results and Discussion  
 
 51  
 
5.3 Preparation and in vitro characterization of DSS-modified carboxylated 
LNPs with long-term stability for enhanced cellular uptake (III) 
 
After the successful modifications on the LNPs obtained in the previous work, the next step 
was to prepare and characterize different carboxylated lignin polymers, in order to achieve a 
long-term stability of the LNPs at physiological conditions, so that their cargos would be 
protected for longer times upon in vivo administration. Afterwards, the optimally carboxylated 
lignin was used to produce LNPs that were further functionalized with a Asp-Ser-Ser (DSS). 
The DSS polypeptide, derived from dentin phosphophoryn, is a repetitive DSS-rich domain 
that facilitates non-receptor-mediated endocytosis, acting like the CPP.325 Additionally, the 
cellular uptake of DSS-functionalized LNPs in three different cancer cell lines was compared 
to corresponding iRGD-functionalized LNPs, using 2D and 3D cell culture models. 
 
 
5.3.1 Characterization of carboxylated lignin and evaluation of long-term stability of 
carboxylated LNPs 
 
The carboxylation reaction was performed as described in the previous work. In this study, 
different ratios of the lignin:succinic anhydride were tested in order to find a balance between 
the carboxylation degree of the lignin polymer and the long-term stability of LNPs at 
physiological conditions. 
In order to confirm the success of the carboxylation reaction, the ATR−FTIR spectra 
were recorded to qualitatively analyze and compare the prepared carboxylated lignin polymers 
with the original lignin polymer (Figure 13A). Besides the typical bands shown on both original 
and carboxylated lignin polymers, as already described above, all the carboxylated lignin 
polymers exhibited a stronger adsorption band at ca. 1720 cm−1 compared to the original lignin, 
which is predominantly due to the stretching vibrations of C=O on the free –COOH groups on 
the carboxylated lignin structure. In addition, an increase on this adsorption band was 
observed according to the degree of carboxylation, suggesting that the reaction was 
successfully accomplished. 
The resulting carboxylated lignin polymers were quantitatively characterized using 31P 
NMR spectroscopy to determine the aliphatic and phenolic –OH groups, as well as the carboxyl 
groups present on the lignin polymers (Figure 13B). The amount of –COOH present in the 
original lignin was 0.455 mmol/g, and it increased after the carboxylation reaction from 0.985 
mmol/g for the ratio 5:1 to 2.280 mmol/g for the ratio 1:2, although this increase was not linearly 
correlated. Consistently, the decrease on the aliphatic and total phenolic –OH groups 
accompanied the increase on the carboxyl groups, suggesting that the hydroxyl groups on the 
original lignin structure were successfully reacted with succinic anhydride.  
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Figure 13. Characterization of the carboxylated lignin polymers after carboxylation reaction 
using different lignin:succinic anhydride ratios by (A) ATRFTIR spectra and (B) quantitative 
31P NMR measurements. Evaluation of the long-term stability of LNPs prepared with the 
different carboxylated lignin by evaluating the dissolution rate of the LNPs after incubation of 
(C) 50 μg/mL, (D) 200 μg/mL and (E) 500 μg/mL in PBS buffer (pH 7.4) up to 72 h. Results are 
shown as mean ± s.d. (n = 3).  
 
 
A dissolution experiment with the LNPs was done to evaluate the long-term stability of 
the LNPs at physiological conditions, in order to select the ideal carboxylated lignin polymer to 
prepare the LNPs for further experiments. For that, LNPs were prepared using the different 
carboxylated polymers previously synthesized with the lignin:succinic anhydride ratios of 1:2 
[LNPs (1:2)], 1:1 [LNPs (1:1)], 2:1 [LNPs (2:1)], 3:1 [LNPs (3:1)], 4:1 [LNPs (4:1)], and 5:1 
[LNPs (5:1)], by the solvent exchange method. Next, LNPs at concentrations of 50 μg/mL 
(Figure 13C), 200 μg/mL (Figure 13D), and 500 μg/mL (Figure 13) were incubated in PBS 
(pH 7.4) to mimic the physiological pH, at 37 °C, up to 72 h. The LNPs (1:2) were dissolved 
instantly after incubation (data not shown). The LNPs (1:1) showed a complete dissolution after 
4 h for the three concentrations of LNPs tested. Both LNPs (2:1) and LNPs (3:1) experienced 
a concentration-dependent dissolution over time. A similar trend for the dissolution of LNPs 
(4:1) and LNPs (5:1) was noticed, but no significant differences on the dissolution rate between 
these two LNPs were observed, in particular for the two highest concentrations of LNPs. After 
48 h, at 50, 200, and 500 μg/mL, the dissolution of the LNPs (4:1) was about 24, 13, and 11%, 
and 18, 11, and 8% for the LNPs (5:1), respectively. In general, the dissolution of the LNPs 
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increased according to the increase on the amount of –COOH groups on the carboxylated 
lignin polymers. This effect can be attributed to the conversion of carboxylic acids into 
carboxylates, due to the sodium and potassium ions present in the PBS buffer in a basic 
environment that reacted with the carboxylic acids. Typically, presenting pKa values ranging 
from 3 to 5 in aqueous media at basic pH, the carboxylic acids can be ionized and converted 
into cationic carboxylates and, consequently, improve their water solubility at basic pH.326 Here, 
the NP dissolution seemed to be dependent on the LNP concentration in PBS buffer, because 
at lower LNP concentration (50 μg/mL), the dissolution was more pronounced as the amount 
of ions in the PBS buffer was higher. Furthermore, the NP dissolution rate appeared to reach 
a constant value after a certain carboxylation degree, as it could be observed for both LNPs 
(4:1) and LNP (5:1). This suggests that some degree of dissolution of LNPs will occur, at any 
carboxylation degree. 
Based on these observations, the ratio 4:1 of lignin:succinic anhydride was the best 
option to prepare the LNPs (4:1) and carry out the following experiments, because it offered 
more than two times higher amounts of carboxyl groups (1.132 mmol/g) than the original lignin, 
and also a good stability at physiological conditions for over 72 h.  
 
 
5.3.2 CellNP interaction studies 
 
The material composition, hydrophobicity/hydrophilicity, size, shape, and surface charge of 
NPs are important parameters that influence the interactions of the NPs with cells and, 
therefore, the cytocompatibility and cellular uptake.162,327 In addition to that, the NP surface 
functionalization with peptides can be done to increase the cellular uptake of the NPs into 
different types of cells and tissues.237,328 Here, the cellular interaction/uptake of the LNPs was 
evaluated with three different cell lines, both qualitatively and quantitatively, by confocal 
microscopy and flow cytometry, respectively. For that purpose, a highly stable fluorescent dye 
(DiA) was loaded into the LNPs before the surface functionalization with iRGD or DSS. The 
cellular uptake of the bare and peptide-functionalized LNPs was evaluated after incubation 
with PC3-MM2, MDA-MB-231, and A549 cells during 3 h, using the conventional in vitro 2D 
cell culture model (Figure 14). According to the confocal images, there was an increase in the 
interaction of both LNPs-iRGD and LNPs-DSS with PC3-MM2 (Figure 14A), MDA-MB-231 
(Figure 14B), and A549 (Figure 14C) cell lines.  
In order to quantify the cellular uptake, the extracellular fluorescence was quenched with 
trypan blue, before analysis by flow cytometry (Figure 14D-I). For the PC3-MM2, both the 
peptide-functionalized LNPs showed a statistically significantly higher cellular uptake than the 
bare LNPs, and the LNPs-DSS showed a higher internalization rate than LNPs-iRGD (Figure 
14D). The mean fluorescence intensity (MFI) values obtained also confirmed these 
observations (Figure 14E). In addition, the LNPs-DSS showed more internalization than LNPs 
and LNPs-iRGD for both MDA-MB-231 (Figure 14F and 14G) and A549 (Figure 14H and 14I) 
cells. However, the LNPs showed higher internalization than the LNPs-iRGD for A549, which 
could be due to a non-specific binding and clustering of negatively charged NPs, such as the 
–COOH modified NPs, on cationic sites on the plasma membrane, leading to higher 
internalization.306 Guarnieri et al. (2014) also showed that the cellular internalization of 
−COOH-modified silica NPs was higher than of the −NH2 counterpart.329 Therefore, and in a 
similar way, the surface characteristics of the bare LNPs could also lead to an increased 
cellular uptake in A549 compared to the LNPs-iRGD. 
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Figure 14. In vitro cellular interaction studies using a 2D cell culture model: (A-C) 
Confocal fluorescence microscopy images of (A) PC3-MM2, (B) MDA-MB-231 and (C) A549 
cell lines, after incubation with 100 μg/mL of bare and peptide-functionalized DiA@LNPs for 3 
h at 37 °C. DAPI (blue), DiA (green), and CellMask Red (red) were used to stain the nucleus, 
the LNPs, and the cell membrane, respectively. The merged panels show the association of 
the LNPs with the cell membrane. Scale bars are 50 μm. Quantitative cellular uptake by flow 
cytometry, after incubation of 100 μg/mL of LNPs with (D) PC3-MM2, (F) MDA-MB-231, and 
(H) A549, for 3 h at 37 °C, in which the LNPs (green) LNPs-iRGD (yellow) and LNPs-DSS (red) 
were compared to the untreated control (grey). MFI quantification for (E) PC3-MM2, (G) MDA-
MB-231, and (I) A549 before and after treatment with the DiA@LNPs. At least 10000 events 
were collected for each measurement. The error bars show the mean ± s.d. (n = 3). Statistical 
significance was set at probabilities of *p < 0.05, **p < 0.01 and ***p < 0.001, and ns is non-
significant. 
 
 
The in vitro cellular uptake of NPs is conventionally evaluated using a 2D model in a flat cell 
culturing surface, a model that does not represent the morphology and 3D organization of the 
native tissues. Consequently, the cell−cell interactions are not realistic, which can lead to a 
misinterpretation of the cellular uptake and consequent biological efficacy of the NPs 
compared to the 3D culturing models.330–332 Thus, the cellular interactions/uptake of bare and 
peptide-functionalized LNPs were evaluated with the same cell lines using the 3D tumor 
spheroids (ca. 600 µm of diameter), and compared with the conventional 2D model. The 
confocal microscopy images of the tumor spheroids showed that both the peptide-
functionalized LNPs improved the interaction with the three cell lines, compared to the bare 
LNPs (Figure 15A-C). For PC3-MM2 and A549 cells, the LNPs-DSS showed an increased 
interaction compared to the LNPs-iRGD. Additionally, the tumor spheroids were disassembled 
after the incubation with the LNPs, the extracellular fluorescence was quenched after 
incubation with trypan blue, and the cellular uptake was then quantified by flow cytometry. For 
the PC3-MM2, the cellular uptake of the LNPs-DSS was found to be significantly higher than 
the LNPs-iRGD and bare LNPs (Figure 15D and 15E). Regarding the MDA-MB-231, the two 
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peptide-modified LNPs showed increased cellular internalization compared to the bare LNPs 
(Figure 15F and 15G). As for the A549 cells, the same trend was observed for the cellular 
uptake of LNPs, and the LNPs-DSS showed an improved cellular internalization compared to 
the LNPs-iRGD and LNPs (Figure 15H and 15I).  
 
 
Figure 15. In vitro cellular interaction studies using 3D tumor spheroids: (A-C) Confocal 
fluorescence microscopy images of (A) PC3-MM2, (B) MDA-MB-231 and (C) A549 cell lines, 
after incubation with 100 μg/mL of bare and peptide-functionalized DiA@LNPs for 3 h at 37 °C. 
DAPI (blue) and DiA (green) were used to stain the nucleus and the LNPs, respectively. The 
merged panels show the association of the LNPs with the tumor spheroid. Scale bars are 200 
μm. Quantitative cellular uptake by flow cytometry, after incubation of 100 μg/mL of LNPs with 
(D) PC3-MM2, (F) MDA-MB-231, and (H) A549, for 3 h at 37 °C, in which the LNPs (green) 
LNPs-iRGD (yellow) and LNPs-DSS (red) were compared to the untreated control (grey). MFI 
quantification for (E) PC3-MM2, (G) MDA-MB-231, and (I) A549 before and after treatment 
with the DiA@LNPs. At least 5000 events were collected for each measurement. The error 
bars represent mean ± s.d. (n = 3). Statistical significance was set at probabilities of *p < 0.05, 
**p < 0.01 and ***p < 0.001, and ns is non-significant. 
 
 
Comparing the two cell culturing models, the cellular uptake of the LNPs was expectably higher 
for the 2D cell model than for the 3D tumor spheroids, which is in agreement with the higher 
MFI values obtained for the 2D-cultured cells. This can be correlated with the stronger and 
more realistic cell−cell interactions in the 3D cell culturing model, and also because of the 
effect of the NPs sedimentation on the 2D cell culturing plate.333 
Although both the peptide-modified LNPs were generally internalized more efficiently in 
both the cell culturing models in the three cell lines, LNPs-DSS showed a superior cellular 
internalization compared to the LNPs-iRGD in some cases. The iRGD binds to the integrins 
overexpressed in the tumor endothelium, improving the tissue penetration in the tumor, and 
upon cleavage it binds to NRP-1 receptor.334 Even though the dentin phosphophoryn contains 
a conserved RGD domain in several species, the internalization of this DSS polypeptide is not 
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mediated through integrin receptors.325 Moreover, neither clathrin nor the caveolae-mediated 
pathways were responsible for the improved cellular uptake of DSS peptide.325 Additionally, 
the disruption of the microtubules and microfilaments involved in the endocytic process did not 
prevent the endocytosis of the DSS peptide.325 Contrasting with iRGD peptide, the 
internalization of the DSS peptide was not associated with the amount of cellular 
target/receptor for its endocytosis.  
Concluding remarks: the DSS peptide can also be employed to modify the NP’s surface, 
improving the cellular internalization of the NPs into different types of cancer cells through a 
non-receptor-mediated endocytosis and, consequently, releasing different cargos 
intracellularly in an efficient manner for different therapeutic applications. 
 
 
5.4 Skewing M2-like tumor macrophages with mUNO-targeted R848-loaded 
LNPs for enhanced chemotherapy (IV) 
 
Triple-negative breast cancer (TNBC) is characterized by the lack of molecular 
targets/receptors (e.g., estrogen and progesterone or HER2), which are molecular targets of 
different therapeutic agents and, therefore, is associated with a poor prognosis of patients 
compared to other breast cancer subtypes.335 Additionally, TAMs that usually resemble an M2-
like macrophage phenotype constitute up to 50% of the tumor mass in breast cancer, being 
associated to an even worse prognosis, tumor progression and recurrence, and higher risk of 
distant metastases.336–338 Chemotherapy is still the primary established systemic treatment 
choice for patients with both early-stage and advanced-stage TNBC.339 Therefore, targeting of 
therapeutics to TME components, such as TAMs, seems to be an alternative or complementary 
approach to improve the outcome of the TNBC patients.   
In this study, LNPs were loaded with R848, a dual agonist of the toll-like receptors TLR7 
and TLR8 that can induce the repolarization of M2-like macrophages towards M1-like 
macrophages, which present an anti-tumor phenotype that can lead to a controlled tumor 
growth.290 The R848@LNPs were functionalized with a short peptide (CSPGAK, “mUNO”) that 
targets the mannose receptor (CD206), typically overexpressed in the M2-like 
macrophages.340,341 The homing ability of untargeted and targeted R848@LNPs, hereafter 
referred as R848@LNPs-P-FAM and R848@LNPs-P-F-mUNO, respectively, was assessed 
using an orthotopic 4T1 TNBC preclinical model. Afterwards, the therapeutic effect of these 
nanosystems was evaluated to potentiate the antitumor efficacy of a chemotherapeutic 
compound (vinblastine, Vin). Finally, the immunological profile of the cells extracted from the 
tumor tissue of the groups receiving the nanoformulated or free R848 were also compared, 
using flow cytometry. 
 
 
5.4.1 Homing study and ex vivo biodistribution analysis 
 
After the physicochemical characterization of the nanosystems, and the in vitro targeting ability 
towards M2-like macrophages and re-education into the anti-tumor M1-like macrophages, the 
in vivo biodistribution of the prepared nanosystems was evaluated. For that, both 
R848@LNPs-P-FAM and R848@LNPs-P-F-mUNO were injected i.p. in an orthotopic 4T1 
tumor-bearing mice, and their homing ability to the tumor tissue was compared. After 3 h of 
circulation time, mice were sacrificed and their organs were collected and cryo-sectioned for 
ex vivo biodistribution analysis by confocal microscopy (Figure 3A, publication IV). The 
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accumulation of the NPs in the lungs was very low, suggesting that almost no NP aggregates 
were formed. Additionally, the accumulation of both the nanosystems was low in the main 
organs associated to the clearance of NPs (liver, spleen and kidney), which indicated that the 
NPs were either in the bloodstream circulation or cleared out from these organs after 3 h. 
Looking at the tumor tissue sections (Figure 3A and 3B, publication IV), both 
R848@LNPs-P-FAM and R848@LNPs-P-F-mUNO showed similar patterns of accumulation 
in the TAMs at the tumor site, which was quantified by the co-localization of the FAM signal 
and CD206 signal (Figure 3C, publication IV). Here, the percentage of co-localization of both 
channels was about 50% and 60% for R848@LNPs-P-FAM and R848@LNPs-P-F-mUNO, 
respectively. However, when the intensity of the FAM signal was quantified in the CD206+ 
macrophages, the R848@LNPs-P-F-mUNO showed a significantly higher accumulation 
compared to the control R848@LNPs-P-FAM (Figure 3D, publication IV), indicating that the 
mUNO peptide can effectively increase the interaction of R848@LNPs with the M2-like 
macrophages in the TME.  
 
 
5.4.2 Therapeutic study and ex vivo immunological profile of tumor cells 
 
Vin is a vinca alkaloid and microtubule-destabilizing agent that interferes with the cell growth 
and survival, by disrupting the dynamic equilibrium of the microtubules, which blocks the cell 
cycle at the metaphase-anaphase transition in mitosis, leading to the cellular apoptosis.342 For 
this therapeutic study, the water-soluble Vin (Vinblastine sulfate) was selected as the 
chemotherapeutic agent, because it does not interfere with the viability of the M2-like TAMs, 
as they present none or minimal proliferation rates.266  
As a result of the relative toxicity of Vin towards different cell lines compared to other 
chemotherapeutic agents,343 the dose for Vin administration chosen was 1 mg/kg, which was 
co-administered with free R848 or R848@LNPs at ca. 0.125 mg/kg, using the orthotopic 4T1 
TNBC model in immunocompetent Balb/c mice. On day 6 of p.i., mice were randomly sorted 
into 5 groups with tumor volume average of 46–48 mm3, and the treatment administered 
intraperitoneally was: (1) PBS and 5.4% of glucose (Control); (2) Vin and 5.4% of glucose (Vin); 
(3) Vin and free R848 (Vin + R848); (4) Vin and R848@LNPs-P-FAM (Vin + R848@LNPs-P-
FAM); and (5) Vin and R848@LNPs-P-F-mUNO (Vin + R848@LNPs-P-F-mUNO). The 
treatment schedule is shown in Figure 4A (publication IV), where the Vin was co-administered 
with the free and nanoformulated R848 every other day, to enhance the antitumor efficacy. 
The Vin treatment was interrupted due to its toxicity, which ultimately led to the weight loss of 
the mice receiving Vin (Figure S5 in Supporting Information, publication IV). After that, two 
more doses of the free and nanoformulated R848 were given i.p. until the endpoint, which was 
defined at day 18 of p.i., in order to study the immunological profile of the cells in the tumor 
tissues.  
During the course of the treatment, the Vin treatment showed some antitumor activity, 
as the tumor volume decreased compared to the PBS group (Figure 4B, publication IV). 
However, the group receiving the R848@LNPs-P-F-mUNO treatment showed an increased 
antitumor efficacy compared to all the other groups receiving Vin. Interestingly, at the end of 
the treatment, the two groups receiving both Vin and R848@LNPs showed a significant 
decrease in tumor weights, compared to the control group (Figure 4C, publication IV). This is 
in line with the results observed in the homing study, which showed that both the R848@LNPs 
could be accumulated in the CD206+ TAMs, which could be explained by the accumulation of 
both the NPs in the tumor tissue driven by the EPR effect.224 Moreover, the R848@LNPs-P-F-
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mUNO treatment also showed a significant reduction in the tumor weight compared to the 
groups receiving Vin alone or co-administered with free R848. These findings suggested that 
the mUNO targeting of the R848 loaded in a nanocarrier to M2-like macrophages at the tumor 
can improve the efficacy compared to the R848 in the free form, by altering its 
pharmacokinetics and biodistribution upon administration. 
 
Finally, the profile of the immune cell population extracted from the tumors was 
investigated using flow cytometry, and a comparison between the groups receiving the 
nanoformulated or free R848 were carried out (Figure 4D-G, publication IV). Firstly, the 
modifications in the macrophage population on the tumor tissue were assessed, which was 
primarily defined by the presence of the F4/80 marker. Therefore, the CD206 and CD86 
markers were further used to identify the M2- or M1-like macrophages, respectively.269,270 Both 
untargeted and mUNO-targeted R848@LNPs showed an increased level of F4/80+CD86+ 
macrophages, compared to the free R848 (Figure 4D, publication IV), suggesting that the 
delivery of R848 with LNPs can significantly improve the therapeutic effect of R848 on the 
differentiation of M2 macrophages into M1-like phenotype at the tumor tissue. This 
repolarization into M1 macrophages can lead to an anti-tumor response characterized by the 
release of pro-inflammatory signals (e.g., TNF-α, IL-6, and IL-12) and production of 
ROS.263,269,270 Surprisingly, the amount of F4/80+CD206+ in the tumor was higher for both 
treatments with the R848@LNPs than the free R848 (Figure 4E, publication IV). This effect 
can be due to an increase in the M2 polarized macrophages in hypoxic/necrotic areas of the 
tumor, as reported by Galstyan et al. (2019), who found a pronounced tissue necrosis and lack 
of tumor vasculature in treated tumors, and consequent persistence of M2-like macrophages 
after a nanoscale immunoconjugate treatment.344 Additionally, M2 macrophages present in the 
TME are also associated with a poor infiltration of T cells in the tumor, in particular the tumor-
infiltrating lymphocytes (TILs), which is frequently correlated to a poor outcome in cancer 
patients. However, TAMs depletion was shown to restore the T cell migration and infiltration 
into tumors.345 In this way, the CD3 and CD8 markers were used to evaluate the presence of 
TILs or CTLs (CD8+ T cells) in the tumor tissues (Figure 4F, publication IV). The percentage 
of CD3+CD8+ T cells in the tumor was significantly higher for the group receiving the 
R848@LNPs-P-F-mUNO compared with the other two groups, indicating that the re-education 
of M2-macrophages accomplished by mUNO-targeted R848@LNPs was more efficient. This 
might have been a consequence of the reduction of the immunosuppressive microenvironment 
in the tumor that indirectly inhibited the action of CD8+ T cells, and directly inhibited T cell 
cytotoxicity caused by the release of ARG1, which ultimately prevents the T cell 
activation.346,347 Therefore, the tumor infiltration of CTLs can induce an immune response 
against the tumor, characterized by IFN-γ secretion.348 Primarily characterized by the 
expression of CD11c, the DCs’ population was also evaluated in the tumor tissues, in particular 
the percentage of activated CD86+ DCs (Figure 4G, publication IV). Generally, the delivery of 
R848 by LNPs led to an increased percentage of CD86 positive DCs in the tumor, compared 
to the free R848. The infiltration of tumor tissues by APCs (such as DCs) is also an important 
prognostic factor in the treatment of cancer, because it can provide a second stimulatory signal 
to start the anti-tumor T cell response.346 
The repeated systemic administration of TLR agonists, such as R848, is not a common 
practice in the clinic, mainly due to its systemic side effects (e.g., fever and headache).349 
However, the delivery of R848 using a nanocarrier can alter the biodistribution of the R848 and 
increase its accumulation and efficacy in modifying the immunological profile of the cells in the 
TME, which was not possible with the systemic administration of free R848. In addition, the 
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use of mUNO-modified LNP to target the M2 macrophages showed an improved efficiency of 
the R848 in different ways. Therefore, the co-administration of R848@LNPs allowed an 
improvement of the administered drug in a very aggressive cancer tumor with a poor prognosis, 
such as the TNBC. 
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6 Conclusions 
 
Lignin has been recently employed for high-value added applications, such as drug delivery. 
The key goal of this thesis was to provide new insights on the use of the unexploited lignin 
polymer to develop and characterize LNPs for anticancer drug delivery applications.  
Firstly, three different LNPs were prepared by a solvent exchange process, with a 
spherical shape and negative surface charge that provided a good colloidal stability. 
Additionally, they exhibited good cytocompatibility towards different cell lines. LNPs also 
showed the ability to load different poorly water-soluble therapeutic compounds, and improved 
their release profiles at different pH-values. Consequently, the growth inhibition effect of BZL 
in different cell lines was also enhanced after loading into LNPs, which enabled the use of 
these innovative LNPs as drug delivery systems for anti-cancer applications. 
Secondly, a carboxylation reaction was successfully achieved on the original lignin 
polymer, which allowed the surface modification of LNPs with PEG-PHIS and CPP, confirmed 
by the conversion of the surface charge from negative to positive after the conjugation 
reactions, without compromising the cytocompatibility of the LNPs. These nanosystems 
allowed also the loading of a poorly water-soluble cytotoxic agent, BZL, in order to enhance its 
release profile at both pH 5.5 and 7.4, with higher dissolution rates at the acidic pH. 
Furthermore, the functionalization of LNPs with PEG-PHIS-CPP provided an improved 
antiproliferative effect of BZL in different cancer cell lines, but a decreased release of BZL in 
physiological environment, resulting in lower toxicity towards a healthy cell line.  
After preparing lignin polymers with different degrees of carboxylation, the optimal ratio 
in terms of stability at physiological conditions was used to prepare LNPs, which were further 
modified with a novel DSS peptide, and the cellular internalization was compared with the 
LNPs-iRGD, using both 2D and 3D cell culturing models. Overall, the LNPs-DSS exhibited 
similar or increased cellular internalization compared with the LNPs-iRGD, indicating that the 
DSS can also be used as a targeting ligand to enhance the intracellularly delivery of cargos. 
Finally, the LNPs were shown to effectively alter the in vivo biodistribution of the 
nanoparticulate R848 compared to the free R848, in enhanced chemotherapy using an 
aggressive tumor model, such as the orthotopic 4T1 TNBC. In addition, the use of mUNO-
modified LNPs showed an improved accumulation and efficacy of the R848 in the tumor, by 
targeting the M2 macrophages. This was achieved by altering the immunological profile of the 
cells in the TME, such as macrophages, while promoting the infiltration of the tumor by 
cytotoxic T cells and dendritic cells.  
Overall, lignin-based systems were developed in this thesis by solvent exchange, and 
further surface functionalization with targeting moieties was done to improve the delivery of 
poorly water-soluble compounds and, ultimately, to enhance cancer therapy. However, there 
are some limitations regarding the manufacture of these nanosystems using bulk methods, 
such as time-consumption, reproducibility and scalability, which are important factors when 
considering the commercialization and translation of such nanosystems into the clinic. A 
continuation of this work would be to use, for example, the microfluidic technique to produce 
LNPs in a more controlled and reproducible manner. The preparation of other lignin-based 
materials, such as hydrogels, could also be useful to achieve a more controlled drug release 
of therapeutics in the tumor, in order to avoid multiple administrations of nanoparticulate 
systems. Additionally, further studies using a combination with checkpoint inhibitors (e.g., anti-
PD1 and anti-CTLA4 antibodies) could increase the efficacy of the in vivo treatment with R848-
loaded LNPs. This combination could also be tested in other types of cancer, such as a highly 
immunogenic tumor type melanoma.  
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